Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV by United States Department of Health and Human Services. Panel on Clinical Practices for the Treatment of HIV Infection.
Morbidity and Mortality Weekly Report
Recommendations and Reports May 17, 2002 / Vol. 51 / No. RR-7
Centers for Disease Control and Prevention
SAFER   •   HEALTHIER   •   PEOPLETM
INSIDE: Continuing Education Examination
Guidelines for Using Antiretroviral Agents
Among HIV-Infected Adults and Adolescents
Recommendations of the Panel on Clinical Practices
for Treatment of HIV
MMWR
SUGGESTED CITATION
Centers for Disease Control and Prevention.
Guidelines for using antiretroviral agents
among HIV-infected adults and adolescents:
recommendations of the Panel on Clinical Practices
for Treatment of HIV. MMWR 2002;51(No. RR-
7):[inclusive page numbers].
The MMWR series of publications is published by the
Epidemiology Program Office, Centers for Disease
Control and Prevention (CDC), U.S. Department of
Health and Human Services,  Atlanta, GA 30333.
Centers for Disease Control and Prevention
David W. Fleming, M.D.
Acting Director
Julie L. Gerberding, M.D.
Acting Deputy Director for Science and Public Health
Dixie E. Snider, Jr., M.D., M.P.H.
Associate Director for Science
Epidemiology Program Office
Stephen B. Thacker, M.D., M.Sc.
Director
Office of Scientific and Health Communications
John W. Ward, M.D.
Director
Editor, MMWR Series
Suzanne M. Hewitt, M.P.A.
Managing Editor










Testing for Plasma HIV RNA Levels and CD4+ T Cell Count
To Guide Decisions Regarding Therapy ............................. 2
Drug-Resistance Testing ....................................................... 3
Using Resistance Assays in Clinical Practice ....................... 4
Considerations for Patients with Established HIV Infection .... 5
Considerations for Initiating Therapy for the Patient
with Asymptomatic HIV Infection ...................................... 5
Considerations for Discontinuing Therapy ............................ 7
Adherence to Potent Antiretroviral Therapy .......................... 8
Adherence to Therapy During HIV Disease ........................ 8
Approaching the Patient .................................................... 8
Directly Observed Therapy .............................................. 10
Therapy Goals ................................................................... 10
Tools for Achieving Therapy Goals ................................... 11
Initiating Therapy for the Asymptomatic
HIV-Infected Patient ........................................................ 11
Initiating Therapy for the Patient with Advanced
HIV Disease ................................................................... 12
HAART-Associated Adverse Clinical Events ......................... 13
Lactic Acidosis and Hepatic Steatosis ............................... 13
Hepatotoxicity ................................................................. 14
Hyperglycemia ................................................................ 15
Fat Maldistribution .......................................................... 15
Hyperlipidemia ............................................................... 15
Increased Bleeding Episodes Among Patients
with Hemophilia .......................................................... 16
Osteonecrosis, Osteopenia, and Osteoporosis ................ 16
Skin Rash ........................................................................ 17
Interruption of Antiretroviral Therapy ................................. 17
Changing a Failing Regimen ............................................. 18
Criteria for Changing Therapy ........................................ 19
Therapeutic Options When Changing Antiretroviral
Therapy ....................................................................... 20
Acute HIV Infection ............................................................ 20
Treatment Regimen for Primary HIV Infection .................. 21
Patient Follow-Up ........................................................... 21
Duration of Therapy for Primary HIV Infection ................. 21
Considerations for Antiretroviral Therapy Among
HIV-Infected Adolescents ................................................ 21
Considerations for Antiretroviral Therapy Among
HIV-Infected Pregnant Women ........................................ 22
Prevention Counseling for the HIV-Infected Patient ............. 25
Conclusion ........................................................................ 26
References ......................................................................... 26
List of Abbreviations Used in This Report ............................ 55
Continuing Education Examination ................................. CE-1On the cover: Transmission electron micrograph of human
immunodeficiency virus type 1, budding and free.
Courtesy of Alyne Harrison, Erskine Palmer, Paul Feorino.
Note: Data regarding use of hydroxyurea in combination with
antiretroviral agents are limited; therefore, this report does
not include recommendations regarding its use in treating
persons infected with human immunodeficiency virus.
Vol. 51 / RR-7 Recommendations and Reports 1
Guidelines for Using Antiretroviral Agents
Among HIV-Infected Adults and Adolescents
Recommendations of the Panel on Clinical Practices for Treatment of HIV*
Prepared by
Mark Dybul, M.D.1
Anthony S. Fauci, M.D.1
John G. Bartlett, M.D.2
Jonathan E. Kaplan, M.D.3
Alice K. Pau, Pharm.D.1




3Division of AIDS, STD, and TB Laboratory Research
National Center for Infectious Diseases
and Division of HIV/AIDS Prevention — Surveillance and Epidemiology
National Center for HIV, STD, and TB Prevention, CDC
Atlanta, Georgia
Summary
The availability of an increasing number of antiretroviral agents and the rapid evolution of new information has introduced
substantial complexity into treatment regimens for persons infected with human immunodeficiency virus (HIV). In 1996, the
Department of Health and Human Services and the Henry J. Kaiser Family Foundation convened the Panel on Clinical Practices
for the Treatment of HIV to develop guidelines for clinical management of HIV-Infected adults and adolescents (CDC. Report of
the NIH Panel To Define Principles of Therapy of HIV Infection and Guidelines for the use of antiretroviral agents in
HIV-infected adults and adolescents. MMWR 1998;47[RR-5]:1–41). This report, which updates the 1998 guidelines, ad-
dresses 1) using testing for plasma HIV ribonucleic acid levels (i.e., viral load) and CD4+ T cell count; 2) using testing for
antiretroviral drug resistance; 3) considerations for when to initiate therapy; 4) adherence to antiretroviral therapy; 5) consider-
ations for therapy among patients with advanced disease; 6) therapy-related adverse events; 7) interruption of therapy; 8) consid-
erations for changing therapy and available therapeutic options; 9) treatment for acute HIV infection; 10) considerations for
antiretroviral therapy among adolescents; 11) considerations for antiretroviral therapy among pregnant women; and 12) concerns
related to transmission of HIV to others.
Antiretroviral regimens are complex, have serious side effects, pose difficulty with adherence, and carry serious potential conse-
quences from the development of viral resistance because of nonadherence to the drug regimen or suboptimal levels of antiretroviral
agents. Patient education and involvement in therapeutic decisions is critical. Treatment should usually be offered to all patients
with symptoms ascribed to HIV infection. Recommendations for offering antiretroviral therapy among asymptomatic patients
require analysis of real and potential risks and benefits. Treatment should be offered to persons who have <350 CD4+ T cells/mm3
or plasma HIV ribonucleic acid (RNA) levels of >55,000 copies/mL (by b-deoxyribonucleic acid [bDNA] or reverse transcriptase-
polymerase chain reaction [RT-PCR] assays). The recommendation to treat asymptomatic patients should be based on the willing-
ness and readiness of the person to begin therapy; the degree of existing immunodeficiency as determined by the CD4+ T cell count;
the risk for disease progression as determined by the CD4+ T cell count and level of plasma HIV RNA; the potential benefits and
risks of initiating therapy in an asymptomatic person; and the likelihood, after counseling and education, of adherence to the
prescribed treatment regimen.
Treatment goals should be maximal and durable suppression of viral load, restoration and preservation of immunologic func-
tion, improvement of quality of life, and reduction of HIV-related morbidity and mortality. Results of therapy are evaluated
through plasma HIV RNA levels, which are expected to indicate
a 1.0 log10 decrease at 2–8 weeks and no detectable virus (<50
copies/mL) at 4–6 months after treatment initiation. Failure of
therapy at 4–6 months might be ascribed to nonadherence, inad-
equate potency of drugs or suboptimal levels of antiretroviral agents,
viral resistance, and other factors that are poorly understood. Pa-
The material in this report was prepared for publication by the National Center
for HIV, STD, and TB Prevention, Harold W. Jaffe, M.D., Acting Director,
and the Division of HIV/AIDS Prevention — Surveillance and Epidemiology,
Robert S. Janssen, M.D., Director.
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† In this report, an adolescent is defined as a person in late puberty or stage V of
the Tanner growth chart (i.e., sexually mature).
§ The panel’s reports and updates are available from the HIV/AIDS Treatment
Information Service (ATIS) (800-448-0440; TTY, 888-480-3739; or Fax, 301-
519-6616) and on the ATIS Internet site at http://www.hivatis.org. They are
also available from the National Prevention Information Network (NPIN)
Internet site at http://www.cdcnpin.org.
Introduction
This report was developed by the Panel on Clinical Prac-
tices for Treatment of HIV (the Panel), which was convened
by the Department of Health and Human Services (DHHS)
and the Henry J. Kaiser Family Foundation in 1996. The goal
of these recommendations is to provide evidence-based guid-
ance for clinicians and other health-care providers who use
antiretroviral agents in treating adults and adolescents† infected
with human immunodeficiency virus (HIV), including preg-
nant women. Although the pathogenesis of HIV infection and
the general virologic and immunologic principles underlying
the use of antiretroviral therapy are similar for all HIV-infected
persons, unique therapeutic and management considerations
exist for HIV-infected children. Therefore, guidance for
antiretroviral therapy for pediatric HIV infection is not con-
tained in this report. A separate report addresses pediatric-
specific concerns related to antiretroviral therapy and is
available at http://www.hivatis.org.
These guidelines serve as a companion to the therapeutic
principles from the National Institutes of Health (NIH) Panel
To Define Principles of Therapy of HIV Infection (1). To-
gether, the reports provide pathogenesis-based rationale for
therapeutic strategies as well as guidelines for implementing
these strategies. Although the guidelines represent the state of
knowledge regarding the use of antiretroviral agents, this is an
evolving science and the availability of new agents or new clini-
cal data regarding the use of existing agents will change thera-
peutic options and preferences. Because this report needs to
be updated periodically, a subgroup of the Panel on Clinical
Practices for Treatment of HIV Infection, the Antiretroviral
Working Group, meets monthly to review new data. Recom-
mendations for changes are then submitted to the Panel and
incorporated as appropriate.§ These recommendations are not
intended to supercede the judgment of clinicians who are
knowledgeable in the care of HIV-infected persons. Further-
more, the Panel recommends that, when possible, the treat-
ment of HIV-infected patients should be directed by a clinician
who has extensive experience in the care of these patients. When
this is not possible, the patient should have access to such
clinical experience through consultations.
Each recommendation is accompanied by a rating that in-
cludes a letter and a Roman numeral (Table 1) and is similar
to the rating schemes used in previous guidelines concerning
prophylaxis of opportunistic infections (OIs) issued by the
U.S. Public Health Service and the Infectious Diseases Soci-
ety of America (2). The letter indicates the strength of the
recommendation, which is based on the opinion of the Panel,
and the Roman numeral reflects the nature of the evidence
supporting the recommendation (Table 1). Thus, recommen-
dations made on the basis of data from clinical trials with
clinical results are differentiated from those made on the basis
of laboratory results (e.g., CD4+ T lymphocyte count or plasma
HIV ribonucleic acid [RNA] levels). When clinical trial data
are unavailable, recommendations are made on the basis of
the opinions of persons experienced in the treatment of HIV
infection and familiar with the relevant literature.
Testing for Plasma HIV RNA Levels
and CD4+ T Cell Count To Guide
Decisions Regarding Therapy
Decisions regarding initiation or changes in antiretroviral
therapy should be guided by monitoring the laboratory pa-
rameters of plasma HIV RNA (viral load) and CD4+ T cell
count in addition to the patient’s clinical condition. Results
of these laboratory tests provide clinicians with key informa-
tion regarding the virologic and immunologic status of the
patient and the risk for disease progression to acquired immu-
nodeficiency syndrome (AIDS) (3,4). HIV viral load testing
has been approved by the Food and Drug Administration
(FDA) for determining prognosis and for monitoring the re-
sponse to therapy only for the reverse transcriptase-polymerase
tients whose therapy fails in spite of a high level of adherence to the regimen should have their regimen changed; this change should
be guided by a thorough drug treatment history and the results of drug-resistance testing. Because of limitations in the available
alternative antiretroviral regimens that have documented efficacy, optimal changes in therapy might be difficult to achieve for
patients in whom the preferred regimen has failed. These decisions are further confounded by problems with adherence, toxicity,
and resistance. For certain patients, participating in a clinical trial with or without access to new drugs or using a regimen that
might not achieve complete suppression of viral replication might be preferable. Because concepts regarding HIV management are
evolving rapidly, readers should check regularly for additional information and updates at the HIV/AIDS Treatment Information
Service website (http://www.hivatis.org).
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chain reaction (RT- PCR) assay and in vitro nucleic amplifi-
cation test for HIV-RNA (NucliSens® HIV-1 QT, manufac-
tured by Organon Teknika). Multiple analyses among >5,000
patients who participated in approximately 18 trials with viral
load monitoring indicated a statistically significant dose-
response–type association between decreases in plasma vire-
mia and improved clinical outcome on the basis of standard
results of new AIDS-defining diagnoses and survival. This re-
lationship was observed throughout a range of patient baseline
characteristics, including pretreatment plasma RNA level,
CD4+ T cell count, and previous drug experience. Thus, viral
load testing is an essential parameter in deciding to initiate or
change antiretroviral therapies. Measurement of plasma HIV
RNA levels (i.e., viral load) by using quantitative methods
should be performed at the time of diagnosis and every 3–4
months thereafter for the untreated patient (AIII) (Table 2).
CD4+ T cell counts should be measured at the time of diagno-
sis and every 3–6 months thereafter (AIII). These intervals
between tests are recommendations only, and flexibility should
be exercised according to the circumstances of each patient.
Plasma HIV RNA levels should also be measured immedi-
ately before and again at 2–8 weeks after initiation of
antiretroviral therapy (AIII). This second measurement allows
the clinician to evaluate initial therapy effectiveness because,
for the majority of patients, adherence to a regimen of potent
antiretroviral agents should result in a substantial decrease (~1.0
log
10
) in viral load by 2–8 weeks. A patient’s viral load should
continue to decline during the following weeks and, for the
majority of patients, should decrease below detectable levels
(i.e., defined as <50 RNA copies/mL of plasma) by 16–24
weeks. Rates of viral load decline toward undetectable are af-
fected by the baseline CD4+ T cell count, the initial viral load,
potency of the regimen, adherence to the regimen, previous
exposure to antiretroviral agents, and the presence of any OIs.
These differences must be considered when monitoring the
effect of therapy. However, the absence of a virologic response
of the magnitude discussed previously should prompt the cli-
nician to reassess patient adherence, rule out malabsorption,
consider repeat RNA testing to document lack of response, or
consider a change in drug regimen. After the patient is on
therapy, HIV RNA testing should be repeated every 3–4
months to evaluate the continuing effectiveness of therapy
(AII). With optimal therapy, viral levels in plasma at 24 weeks
should be undetectable (5). Data from clinical trials demon-
strate that lowering plasma HIV RNA to <50 copies/mL is
associated with increased duration of viral suppression, com-
pared with reducing HIV RNA to levels of 50–500 copies/
mL (6). If HIV RNA remains detectable in plasma after 16–
24 weeks of therapy, the plasma HIV RNA test should be
repeated to confirm the result and a change in therapy should
be considered (see Changing a Failing Regimen) (BIII).
When deciding on therapy initiation, the CD4+ T lympho-
cyte count and plasma HIV RNA measurement should be
performed twice to ensure accuracy and consistency of mea-
surement (BIII). However, among patients with advanced HIV
disease, antiretroviral therapy should be initiated after the first
viral load measurement is obtained to prevent a potentially
deleterious delay in treatment. The requirement for two mea-
surements of viral load might place a substantial financial bur-
den on patients or payers. Nonetheless, the Panel believes that
two measurements of viral load will provide the clinician with
the best information for subsequent patient follow-up. Plasma
HIV RNA levels should not be measured during or within 4
weeks after successful treatment of any intercurrent infection,
resolution of symptomatic illness, or immunization. Because
differences exist among commercially available tests, confir-
matory plasma HIV RNA levels should be measured by using
the same laboratory and the same technique to ensure consis-
tent results.
A minimal change in plasma viremia is considered to be a
threefold or 0.5-log
10
 increase or decrease. A substantial de-
crease in CD4+ T lymphocyte count is a decrease of >30%
from baseline for absolute cell numbers and a decrease of >3%
from baseline in percentages of cells (7). Discordance between
trends in CD4+ T cell numbers and plasma HIV RNA levels
was documented among 20% of patients in one cohort stud-
ied (8). Such discordance can complicate decisions regarding
antiretroviral therapy and might be caused by factors that af-
fect plasma HIV RNA testing. Viral load and trends in viral
load are believed to be more informative for decision-making
regarding antiretroviral therapy than are CD4+ T cell counts;
however, exceptions to this rule do occur (see Changing a Fail-
ing Regimen). In certain situations, consultation with a spe-
cialist should be considered.
Drug-Resistance Testing
Testing for HIV resistance to antiretroviral drugs is a useful
tool for guiding antiretroviral therapy. When combined with
a detailed drug history and efforts in maximizing drug adher-
ence, these assays might maximize the benefits of antiretroviral
therapy. Studies of treatment-experienced patients have re-
ported strong associations between the presence of drug resis-
tance, identified by genotyping or phenotyping resistance
assays, and failure of the antiretroviral treatment regimen to
suppress HIV replication. Genotyping assays detect drug-
resistance mutations that are present in the relevant viral genes
(i.e., reverse transcriptase and protease). Certain genotyping
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¶ Additional information is available at http://hiv-web.lanl.gov.
assays involve sequencing of the entire reverse transcriptase
and protease genes, whereas others use probes to detect se-
lected mutations that are known to confer drug resistance.
Genotyping assays can be performed rapidly, and results can
be reported within 1–2 weeks of sample collection. Interpre-
tation of test results requires knowledge of the mutations that
are selected for by different antiretroviral drugs and of the
potential for cross-resistance to other drugs conferred by cer-
tain mutations.¶ Consultation with a specialist in HIV drug
resistance is encouraged and can facilitate interpretation of
genotypic test results.
Phenotyping assays measure a virus’ ability to grow in dif-
ferent concentrations of antiretroviral drugs. Automated, re-
combinant phenotyping assays are commercially available with
results available in 2–3 weeks; however, phenotyping assays
are more costly to perform, compared with genotypic assays.
Recombinant phenotyping assays involve insertion of the re-
verse transcriptase and protease gene sequences derived from
patient plasma HIV RNA into the backbone of a laboratory
clone of HIV either by cloning or in vitro recombination.
Replication of the recombinant virus at different drug con-
centrations is monitored by expression of a reporter gene and
is compared with replication of a reference HIV strain. Drug
concentrations that inhibit 50% and 90% of viral replication





are calculated, and the ratio of the IC
50
 of the test and refer-
ence viruses is reported as the fold increase in IC
50
 (i.e., fold
resistance). Interpretation of phenotyping assay results is com-
plicated by the paucity of data regarding the specific resis-
tance level (i.e., fold increase in IC
50
) that is associated with
drug failure; again, consultation with a specialist can be help-
ful for interpreting test results. Further limitations of both
genotyping and phenotyping assays include the lack of uni-
form quality assurance for all available assays, relatively high
cost, and insensitivity for minor viral species. If drug-resistant
viruses are present but constitute <10%–20% of the circulat-
ing virus population, they probably will not be detected by
available assays. This limitation is critical when interpreting
data regarding susceptibility to drugs that the patient has taken
in the past but that are not part of the current antiretroviral
regimen. If drug resistance had developed to a drug that was
subsequently discontinued, the drug-resistant virus can be-
come a minor species because its growth advantage is lost (9).
Consequently, resistance assays should be performed while the
patient is taking his or her antiretroviral regimen, and data
substantiating the absence of resistance should be interpreted
cautiously in relation to the previous treatment history.
Using Resistance Assays
in Clinical Practice
Resistance assays can be useful for patients experiencing vi-
rologic failure while on antiretroviral therapy and patients with
acute HIV infection (Table 3). Recent prospective data sup-
porting drug-resistance testing in clinical practice are derived
from trials in which the test utility was assessed for cases of
virologic failure. Two studies compared virologic responses to
antiretroviral treatment regimens when genotyping resistance
tests were available to guide therapy (10,11) with the responses
observed when changes in therapy were guided by clinical judg-
ment only. The results of both studies indicated that the short-
term virologic response to therapy was substantially increased
when results of resistance testing were available. Similarly, a
prospective, randomized, multicenter trial demonstrated that
therapy selected on the basis of phenotypic resistance testing
substantially improves the virologic response to antiretroviral
therapy, compared with therapy selected without the aid of
phenotypic testing (12). Thus, resistance testing appears to be
a useful tool in selecting active drugs when changing
antiretroviral regimens in cases of virologic failure (BII). Similar
rationale applies to the potential use of resistance testing for
patients with suboptimal viral load reduction (see Criteria for
Changing Therapy) (BIII). Virologic failure regarding highly
active antiretroviral therapy (HAART) is, for certain patients,
associated with resistance to one component of the regimen
only (13); in that situation, substituting individual drugs in a
failing regimen might be possible, although this concept re-
quires clinical validation (see Changing a Failing Regimen).
No prospective data exist to support using one type of resis-
tance assay over another (i.e., genotyping versus phenotyping)
in different clinical situations. Therefore, one type of assay is
recommended per sample; however, for patients with a com-
plex treatment history, both assays might provide critical and
complementary information.
Transmission of drug-resistant HIV strains has been docu-
mented and might be associated with a suboptimal virologic
response to initial antiretroviral therapy (14–17). If the deci-
sion is made to initiate therapy in a person with acute HIV
infection, using resistance testing to optimize the initial
antiretroviral regimen is a reasonable, albeit untested, strategy
(18–19) (CIII). Because of its more rapid turnaround time,
using a genotypic assay might be preferred in this situation.
Using resistance testing before initiation of antiretroviral
therapy among patients with chronic HIV infection is not
recommended (DIII) because of uncertainty regarding the
prevalence of resistance among treatment-naïve persons. In
addition, available resistance assays might fail to detect drug-
resistant species that were transmitted when primary infec-
Vol. 51 / RR-7 Recommendations and Reports 5
tion occurred but became a minor species in the absence of
selective drug pressure. Reserving resistance testing for patients
with suboptimal viral load suppression after therapy initia-
tion is preferable, although this approach might change as
additional information becomes available related to the preva-
lence of resistant virus among antiretroviral-naïve patients.
Recommendations for resistance testing during pregnancy
are the same as for nonpregnant women; acute HIV infection,
virologic failure while on an antiretroviral regimen, or subop-
timal viral load suppression after initiation of antiretroviral
therapy are all appropriate indications for resistance testing. If
an HIV-positive pregnant woman is taking an antiretroviral
regimen that does not include zidovudine, or if zidovudine
was discontinued because of maternal drug resistance, intra-
partum and neonatal zidovudine prophylaxis should be ad-
ministered to prevent mother-to-child HIV transmission (see
Considerations for Antiretroviral Therapy Among HIV-
Infected Pregnant Women). Not all of zidovudine’s activity in
preventing mother-to-child HIV transmission can be ac-
counted for by its effect on maternal viral load (20); further-
more, preliminary data indicate that the rate of perinatal
transmission after zidovudine prophylaxis might not differ
between those with and without zidovudine-resistance muta-
tions (21,22). Studies are needed to determine the best strat-
egy to prevent mother-to-child HIV transmission in the
presence of zidovudine resistance.
Considerations for Patients
with Established HIV Infection
Patients with established HIV infection are discussed in two
arbitrarily defined clinical categories: asymptomatic infection
or symptomatic disease (i.e., wasting, thrush, or unexplained
fever for >2 weeks) including AIDS, as classified by CDC in
1993 (23). All patients in the second category should be of-
fered antiretroviral therapy. Initiating antiretroviral therapy
among patients in the first category is complex and, therefore,
discussed separately. However, before initiating therapy for any
patient, the following evaluation should be performed:
• complete history and physical (AII);
• complete blood count, chemistry profile, including se-
rum transaminases and lipid profile (AII);
• CD4+ T lymphocyte count (AI); and
• plasma HIV RNA measurement (AI).
Additional evaluation should include routine tests relevant
to preventing OIs, if not already performed (e.g., rapid plasma
reagin or Venereal Disease Research Laboratory test; tubercu-
lin skin test; toxoplasma immunoglobulin G serology; hepati-
tis B and C serology; and gynecologic exam, including
Papanicolaou smear). Other tests are recommended, if clini-
cally indicated (e.g., chest radiograph and ophthalmologic
exam) (AII). Cytomegalovirus serology can be useful for cer-
tain patients (2) (BIII).
Considerations for Initiating
Therapy for the Patient
with Asymptomatic HIV Infection
Although randomized clinical trials provide strong evidence
for treating patients with <200 CD4+ T cells/mm3 (24–26),
the optimal time to initiate antiretroviral therapy among as-
ymptomatic patients with CD4+ T cell counts >200 cells/mm3
is unknown. For persons with >200 CD4+ T cells/mm3, the
strength of the recommendation for therapy must balance the
readiness of the patient for treatment, consideration of the
prognosis for disease-free survival as determined by baseline
CD4+ T cell count and viral load levels, and assessment of the
risks and potential benefits associated with initiating
antiretroviral therapy.
Regarding a prognosis that is based on the patient’s CD4+ T
cell count and viral load, data are absent concerning clinical
endpoints from randomized, controlled trials for persons with
>200 CD4+ T cells/mm3 to guide decisions on when to ini-
tiate therapy. However, despite their limitations, observational
cohorts of HIV-infected persons either treated or untreated
with antiretroviral therapy provide key data to assist in risk
assessment for disease progression.
Observational cohorts have provided critical data regarding
the prognostic influence of viral load and CD4+ T cell count
in the absence of treatment. These data indicate a strong rela-
tionship between plasma HIV RNA levels and CD4+ T cell
counts in terms of risk for progression to AIDS for untreated
persons and provide potent support for the conclusion that
therapy should be initiated before the CD4+ T cell count de-
clines to <200 cells/mm3 (Figure; Tables 4,5). In addition, these
studies are useful for the identification of asymptomatic per-
sons at high risk who have CD4+ T cell counts >200 cells/
mm3 and who might be candidates for antiretroviral therapy
or more frequent CD4+ T cell count monitoring. Regarding
CD4+ T cell count monitoring, the Multicenter AIDS Co-
hort Study (MACS) demonstrated that the 3-year risk for pro-
gression to AIDS was 38.5% among patients with 201–350
CD4+ T cells/mm3, compared with 14.3% for patients with
CD4+ T cell counts >350 cells/mm3. However, the short-term
risk for progression also was related to the level of plasma HIV
RNA, and the risk was relatively low for those persons with
<20,000 copies/mL. An evaluation of 231 persons with CD4+
T cell counts of 201–350 cells/mm3 demonstrated that the 3-
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year risk for progression to AIDS was 4.1% for the 74 patients
with HIV RNA <20,000; 36.4% for those 53 patients with
HIV RNA 20,001–55,000 copies/mL; and 64.4% for those
104 patients with HIV RNA >55,000 copies/mL. Similar risk
gradations by viral load were evident for patients with CD4+
T cell counts >350 cells/mm3 (Figure; Table 5) (unpublished
data, Alvaro Muñoz, Ph.D., Johns Hopkins University, Balti-
more, Maryland, 2001). These data indicate that for certain
patients with CD4+ T cell counts >200 cells/mm3, the 3-year
risk for disease progression to AIDS in the absence of treat-
ment is substantially increased. Thus, although observational
studies of untreated persons cannot assess the effects of therapy
and, therefore, cannot determine the optimal time to initiate
therapy, these studies do provide key guidance regarding the
risks for progression in the absence of therapy on the basis of
a patient’s CD4+ T cell count and viral load.
Data from observational studies of HAART-treated cohorts
also provide critical information to guide using antiretroviral
therapy among asymptomatic patients (27–30). A collabora-
tive analysis of data from 13 cohort studies from Europe and
North America demonstrates that among drug-naïve patients
without AIDS-defining illness and a viral load of <100,000
copies/mL, the 3-year probability of progression to AIDS or
death was 15.8% among those who initiated therapy with
CD4+ T cell counts of 0–49 cells/mm3; 12.5% among those
with CD4+ T cell counts of 50–99 cells/mm3; 9.3% among
those with CD4+ T cell counts of 100–199 cells/mm3; 4.7%
among those with CD4+ T cell counts of 200–349 cells/mm3;
and 3.4% among those with CD4+ T ell counts of 350 cells/
mm3 or higher (30). These data indicate that the prognosis
might be better for patients who initiate therapy at >200 cells/
mm3; but risk after initiation of therapy does not vary consid-
erably at >200 cells/mm3. However, risk for progression also
was related to plasma HIV RNA levels in this study. A sub-
stantial increase in risk for progression was evident among all
patients with a viral load >100,000 copies/mL. In other co-
hort studies, an apparent benefit in terms of disease progres-
sion was reported among persons who began antiretroviral
therapy when CD4+ T cell counts were >350 cells/mm3, com-
pared with those who deferred therapy (31,32). For example,
in the Swiss cohort study, an approximate 7-fold decrease oc-
curred in disease progression to AIDS among persons who
initiated therapy with a CD4+ T cell count >350 cells/mm3,
compared with those who were monitored without therapy
during a 2-year period (32). However, a substantial incidence
of adverse treatment effects occurred among patients who ini-
tiated therapy; 40% of patients had >1 treatment changes be-
cause of adverse effects, and 20% were no longer receiving
treatment after 2 years (32). Unfortunately, observational stud-
ies of persons treated with HAART also have limitations re-
garding the ability to determine an optimal time to initiate
therapy. The relative risks for disease progression for persons
with CD4+ T cell counts of 200–349 and >350 cells/mm3
cannot be precisely compared because of the low level of dis-
ease progression among these patients during the follow-up
period. In addition, groups might differ in key known and
unknown prognostic factors that bias the comparison.
In addition to the risks for disease progression, the decision
to initiate antiretroviral therapy also is influenced by an as-
sessment of other potential risks and benefits associated with
treatment. Potential benefits and risks of early or delayed
therapy initiation for the asymptomatic patient should be con-
sidered by the clinician and patient (Table 5). Potential ben-
efits of early therapy include 1) earlier suppression of viral
replication; 2) preservation of immune function; 3) prolonga-
tion of disease-free survival; and 4) decrease in the risk for
viral transmission. Risks include 1) the adverse effects of the
drugs on quality of life; 2) the inconvenience of the majority
of the available suppressive regimens, leading to reduced ad-
herence; 3) development of drug resistance because of subop-
timal suppression of viral replication; 4) limitation of future
treatment options as a result of premature cycling of the pa-
tient through the available drugs; 5) the risk for transmission
of virus resistant to antiretroviral drugs; 6) serious toxicities
associated with certain antiretroviral drugs (e.g., elevations in
serum levels of cholesterol and triglycerides, alterations in the
distribution of body fat, or insulin resistance and diabetes
mellitus); and 7) the unknown durability of effect of available
therapies. Potential benefits of delayed therapy include 1) mini-
mization of treatment-related negative effects on quality of
life and drug-related toxicities; 2) preservation of treatment
options; and 3) delay in the development of drug resistance.
Potential risks of delayed therapy include 1) the possibility
that damage to the immune system, which might otherwise
be salvaged by earlier therapy, is irreversible; 2) the possibility
that suppression of viral replication might be more difficult at
a later stage of disease; and 3) the increased risk for HIV trans-
mission to others during a longer untreated period. Finally,
for certain persons, ascertaining the precise time at which the
CD4+ T cell count will decrease to a level where the risk for
disease is high might be difficult, and time might be required
to identify an effective, tolerable regimen. This task might be
better accomplished before reaching a CD4+ T cell count of
200 cells/mm3.
After considering available data in terms of the relative risk
for progression to AIDS at certain CD4+ T cell counts and
viral loads and the potential risks and benefits associated with
initiating therapy, certain specialists in this area believe that
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the evidence supports initiating therapy for asymptomatic HIV-
infected persons with a CD4+ T cell count of <350 cells/mm3
or a viral load of >55,000 copies/mL (by RT-PCR or b-
deoxyribonucleic acid [bDNA] assays). For asymptomatic
patients with CD4+ T cell counts >350 cells/mm3, rationale
exists for both conservative and aggressive approaches to
therapy. The conservative approach is based on the recogni-
tion that robust immune reconstitution still occurs in the
majority of patients who initiate therapy with CD4+ T cell
counts in the 200–350 cells/mm3 range, and that toxicities
and adherence challenges might outweigh benefits of initiat-
ing therapy at CD4+ T cell counts >350 cells/mm3. In the
conservative approach, increased levels of plasma HIV RNA
(i.e., >55,000 by RT-PCR or bDNA assays) are an indication
that more frequent monitoring of CD4+ T cell counts and
plasma HIV RNA levels is needed, but not necessarily for ini-
tiation of therapy. In the aggressive approach, asymptomatic
patients with CD4+ T cell counts >350 cells/mm3 and levels
of plasma HIV RNA >55,000 copies/mL would be treated
because of the risk for immunologic deterioration and disease
progression. The aggressive approach is supported by the ob-
servation in multiple studies that suppression of plasma HIV
RNA by antiretroviral therapy is easier to achieve and main-
tain at higher CD4+ T cell counts and lower levels of plasma
viral load (6,33–36). However, long-term clinical outcome data
are not available to fully endorse this approach.
Data are conflicting regarding sex-specific differences in vi-
ral load and CD4+ T cell counts. Certain studies (37–43),
although not others (44–47), have concluded that after ad-
justment for CD4+ T cell count, levels of HIV RNA are lower
in women than men. In those studies that have indicated a
possible sex difference in HIV RNA levels, women have had
RNA levels that ranged from 0.13 to 0.28 log
10
 lower than
observed among men. In two studies of HIV seroconverters,
HIV RNA copy numbers were substantially lower in women
than men at seroconversion, but these differences decreased
with time; and median viral load in women and men became
similar within 5–6 years after seroconversion (38,39,43). Other
data indicate that CD4+ T cell counts might be higher in
women than men (48). However, importantly, rates of disease
progression do not differ in a sex-dependent manner
(41,43,49,50). Taken together, these data demonstrate that
sex-based differences in viral load occur predominantly dur-
ing a window of time when the CD4+ T cell count is relatively
preserved, when treatment is recommended only in the set-
ting of increased levels of plasma HIV RNA. Clinicians might
consider lower plasma HIV RNA thresholds for initiating
therapy in women with CD4+ T cell counts >350 cells/mm3,
although insufficient data exist to determine an appropriate
threshold. In patients with CD4+ T cell counts <350 cells/
mm3, limited sex-based differences in viral load have been
observed; therefore, no changes in treatment guidelines for
women are recommended for this group.
In summary, the decision to begin therapy for the asymp-
tomatic patient with >200 CD4+ T cells/mm3 is complex and
must be made in the setting of careful patient counseling and
education. Factors that must be considered in this decision
are 1) the willingness, ability, and readiness of the person to
begin therapy; 2) the degree of existing immunodeficiency as
determined by the CD4+ T cell count; 3) the risk for disease
progression as determined by the CD4+ T cell count and level
of plasma HIV RNA (1) (Figure; Tables 5,6); 4) the potential
benefits and risks of initiating therapy for asymptomatic per-
sons, including short- and long-term adverse drug effects (Table
4); and 5) the likelihood, after counseling and education, of
adherence to the prescribed treatment regimen. Regarding
adherence, no patient should automatically be excluded from
consideration for antiretroviral therapy simply because he or
she exhibits a behavior or other characteristic judged by the
clinician to lend itself to nonadherence. Rather, the likelihood
of patient adherence to a long-term, complex drug regimen
should be discussed and determined by the patient and clini-
cian before therapy is initiated. To achieve the level of adher-
ence necessary for effective therapy, providers are encouraged
to use strategies for assessing and assisting adherence: inten-
sive patient education and support regarding the critical need
for adherence should be provided; specific goals of therapy
should be established and mutually agreed upon; and a long-
term treatment plan should be developed with the patient.
Intensive follow-up should occur to assess adherence to treat-
ment and to continue patient counseling for the prevention of
sexual and drug-injection–related transmission (see Adherence
to Potent Antiretroviral Therapy).
Considerations
for Discontinuing Therapy
As recommendations evolve, patients who had begun active
antiretroviral therapy at CD4+ T cell counts of >350/mm3
might consider discontinuing treatment. No clinical data ex-
ist addressing whether this should be done or if it can be ac-
complished safely. Potential benefits include reduction of
toxicity and drug interactions, decreased risk for drug-selecting
resistant variants, and improvement in quality of life. Risks
include rebound in viral replication and renewed immuno-
logic deterioration. If the patient and clinician agree to dis-
continue therapy, the patient should be closely monitored.
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Adherence to Potent
Antiretroviral Therapy
The Panel recommends that certain persons living with HIV,
including persons who are asymptomatic, should be treated
with HAART for the rest of their lives. Adherence to the regi-
men is essential for successful treatment and has been reported
to increase sustained virologic control, which is critical in re-
ducing HIV-related morbidity and mortality. Conversely, sub-
optimal adherence has been reported to decrease virologic
control and has been associated with increased morbidity and
mortality (51,52). Suboptimal adherence also leads to drug
resistance, limiting the effectiveness of therapy (53). The de-
terminants, measurements, and interventions to improve ad-
herence to HAART are insufficiently characterized and
understood, and additional research regarding this topic is
needed.
Adherence to Therapy During HIV
Disease
Adherence is a key determinant in the degree and duration
of virologic suppression. Among studies reporting on the as-
sociation between suboptimal adherence and virologic fail-
ure, nonadherence among patients on HAART was the
strongest predictor for failure to achieve viral suppression be-
low the level of detection (52,53). Other studies have reported
that 90%–95% of doses must be taken for optimal suppres-
sion, with lesser degrees of adherence being associated with
virologic failure (51,54). No conclusive evidence exists that
the degree of adherence required varies with different classes
of agents or different medications in the HAART regimen.
Suboptimal adherence is common. Surveys have determined
that one third of patients missed doses within <3 days of the
survey (55). Reasons for missed doses were predictable and
included forgetting, being too busy, being out of town, being
asleep, being depressed, having adverse side effects, and being
too ill (56). One fifth of HIV-infected patients in one urban
center never filled their prescriptions. Although homelessness
can lead to suboptimal adherence, one program achieved a
70% adherence rate among homeless persons by using flex-
ible clinic hours, accessible clinic staff, and incentives (57).
Predictors of inadequate adherence to HIV medications in-
clude 1) lack of trust between the clinician and patient; 2)
active drug and alcohol use; 3) active mental illness (e.g., de-
pression); 4) lack of patient education and inability of pa-
tients to identify their medications (56); and 5) lack of reliable
access to primary medical care or medication (58). Other
sources of instability influencing adherence include domestic
violence and discrimination (58). Medication side effects can
also cause inadequate adherence as can fear of or experiencing
metabolic and morphologic side effects of HAART (59). Pre-
dictors of optimal adherence to HIV medications, and hence,
optimal viral suppression, include 1) availability of emotional
and practical life supports; 2) a patient’s ability to fit medica-
tions into his or her daily routine; 3) understanding that sub-
optimal adherence leads to resistance; 4) recognizing that taking
all medication doses is critical; 5) feeling comfortable taking
medications in front of others (60); and 6) keeping clinic ap-
pointments (34).
Measurement of adherence is imperfect and lacks established
standards. Patient self-reporting is an unreliable predictor of
adherence; however, a patient’s estimate of suboptimal adher-
ence is a strong predictor and should be strongly considered
(60,61). A clinician’s estimate of the likelihood of a patient’s
adherence is also an unreliable predictor (62). Aids for mea-
suring adherence (e.g., pill counts, pharmacy records, smart
pill bottles with computer chips that record each opening [i.e.,
medication event monitoring systems or MEMS caps]) might
be useful, although each aid requires comparison with patient
self-reporting (61,63). Clinician and patient estimates of the
degree of adherence have been reported to exceed measures
that are based on MEMS caps. Because of its complexity and
cost, MEMS caps technology might be used as an adjunct to
adherence research, but it is not useful in clinical settings.
Self-reporting should include a short-term assessment of each
dose that was taken during the recent past (e.g., <3 days) and
a general inquiry regarding adherence since the last visit, with
explicit attention to the circumstances of missed doses and
possible measures to prevent further missed doses. Having
patients bring their medications and medication diaries to
clinic visits might be helpful also.
Approaching the Patient
Patient-Related Strategies
The first principle of patient-related strategies is to negoti-
ate a treatment plan that the patient understands and to which
he or she commits (Tables 7–10) (64,65). Before writing the
first prescription, clinicians should assess the patient’s readi-
ness to take medication, which might take two or three office
visits and patience. Patient education should include the goals
of therapy, including a review of expected outcomes that are
based on baseline viral load and CD4+ T cell counts (e.g.,
MACS data from the Guidelines [4]), the reason for adher-
ence, and the plan for and mechanics of adherence. Patients
must understand that the first HAART regimen has the best
chance for long-term success (1). Clinicians and health teams
should develop a plan for the specific regimen, including how
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medication timing relates to meals and daily routines. Cen-
ters have offered practice sessions and have used candy in place
of pills to familiarize the patient with the rigors of HAART;
however, no data exist to indicate if this exercise improves
adherence. Daily or weekly pillboxes, timers with alarms, pag-
ers, and other devices can be useful. Because medication side
effects can affect treatment adherence, clinicians should in-
form patients in advance of possible side effects and when
they are likely to occur. Treatment for side effects should be
included with the first prescription, as well as instructions on
appropriate response to side effects and when to contact the
clinician. Low literacy is associated with suboptimal adher-
ence, also. Clinicians should assess a patient’s literacy level
before relying on written information, and they should tailor
the adherence intervention for each patient. Visual aids and
audio or video information sources can be useful for patients
with low literacy (66).
Education of family and friends and their recruitment as
participants in the adherence plan can be useful. Community
interventions, including adherence support groups or the ad-
dition of adherence concerns to other support group agendas,
can aid adherence. Community-based case managers and peer
educators can assist with adherence education and strategies
for each patient.
Temporary postponement of HAART initiation has been
proposed for patients with identified risks for suboptimal ad-
herence (67,68). For example, a patient with active substance
abuse or mental illness might benefit from psychiatric treat-
ment or treatment for chemical dependency before initiating
HAART. During the 1–2 months needed for treatment of these
conditions, appropriate HIV therapy might be limited to OI
prophylaxis, if indicated, and therapy for drug withdrawal,
detoxification, or the underlying mental illness. In addition,
readiness for HAART can be assessed and adherence educa-
tion can be initiated during this period. Other sources of pa-
tient instability (e.g., homelessness) can be addressed during
this time. Patients should be informed and in agreement with
plans for future treatment and time-limited treatment
deferral.
Selected factors (e.g., sex, race, low socioeconomic status or
education level, and past drug use) are not reliable predictors
of suboptimal adherence. Conversely, higher socioeconomic
status and education level and a lack of past drug abuse do not
predict optimal adherence (69). No patient should automati-
cally be excluded from antiretroviral therapy simply because
he or she exhibits a behavior or characteristic judged by the
clinician to indicate a likelihood of nonadherence.
Clinician and Health Team-Related Strategies
Trusting relationships among the patient, clinician, and
health team are essential (Table 8). Clinicians should commit
to communication between clinic visits, ongoing adherence
monitoring, and timely response to adverse events or interim
illness. Interim management during clinician vacations or other
absences must be clarified with the patient.
Optimal adherence requires full participation by the health-
care team, with goal reinforcement by >2 team members. Sup-
portive and nonjudgmental attitudes and behaviors will
encourage patient honesty regarding adherence and problems.
Improved adherence is associated with interventions that in-
clude pharmacist-based adherence clinics (69), street-level
drop-in centers with medication storage and flexible hours for
homeless persons (70), adolescent-specific training programs
(71), and medication counseling and behavioral interventions
(72) (Table 9). For all health-care team members, specific train-
ing regarding HAART and adherence should be offered and
updated periodically.
Monitoring can identify periods of inadequate adherence.
Evidence indicates that adherence wanes as time progresses,
even among patients whose adherence has been optimal, a
phenomenon described as pill fatigue or treatment fatigue
(67,73). Thus, monitoring adherence at every clinic encoun-
ter is essential. Reasonable responses to decreasing adherence
include increasing the intensity of clinical follow-up, shorten-
ing the follow-up interval, and recruiting additional health
team members, depending on the problem (68). Certain pa-
tients (e.g., chemically dependent patients, mentally retarded
patients in the care of another person, children and adoles-
cents, or patients in crisis) might require ongoing assistance
from support team members from the outset.
New diagnoses or symptoms can influence adherence. For
example, depression might require referral, management, and
consideration of the short- and long-term impact on adher-
ence. Cessation of all medications at the same time might be
more desirable than uncertain adherence during a 2-month
exacerbation of chronic depression.
Responses to adherence interventions among specific groups
have not been well-studied. Evidence exists that programs de-
signed specifically for adolescents, women and families, injec-
tion-drug users, and homeless persons increase the likelihood
of medication adherence (69,71,74,75). The incorporation of
adherence interventions into convenient primary care settings;
training and deployment of peer educators, pharmacists, nurses,
and other health-care personnel in adherence interventions;
and monitoring of clinician and patient performance regard-
ing adherence are beneficial (70,76,77). In the absence of data,
a reasonable response is to address and monitor adherence
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during all HIV primary care encounters and incorporate ad-
herence goals in all patient treatment plans and interventions.
This might require the full use of a support team, including
bilingual providers and peer educators for non-English–
speaking populations, incorporation of adherence into sup-
port group agendas and community forums, and inclusion of
adherence goals and interventions in the work of chemical-
dependency counselors and programs.
Regimen-Related Strategies
Regimens should be simplified as much as possible by re-
ducing the number of pills and therapy frequency and by mini-
mizing drug interactions and side effects. For certain patients,
problems with complex regimens are of lesser importance, but
evidence supports simplified regimens with reduced pill num-
bers and dose frequencies (78,79). With the effective options
for initial therapy noted in this report and the observed ben-
efit of less frequent dosing, twice-daily dosing of HAART regi-
mens is feasible for the majority of patients. Regimens should
be chosen after review and discussion of specific food require-
ments and patient understanding and agreement to such re-
strictions. Regimens requiring an empty stomach multiple
times daily might be difficult for patients with a wasting dis-
order, just as regimens requiring high fat intake might be dif-
ficult for patients with lactose intolerance or fat aversion.
However, an increasing number of effective regimens do not
have specific food requirements.
Directly Observed Therapy
Directly observed therapy (DOT), in which a health-care
provider observes the ingestion of medication, has been suc-
cessful in tuberculosis management, specifically among pa-
tients whose adherence has been suboptimal. However, DOT
is labor-intensive, expensive, intrusive, and programmatically
complex to initiate and complete; and unlike tuberculosis, HIV
requires lifelong therapy. Pilot programs have studied DOT
among HIV patients with preliminary success. These programs
have studied once-daily regimens among prison inmates,
methadone program participants, and other patient cohorts
with a record of repeated suboptimal adherence. Modified
DOT programs have also been studied in which the morning
dose is observed and evening and weekend doses were self-
administered. The goal of these programs is to improve pa-
tient education and medication self-administration during a
limited period (e.g., 3–6 months); however, the outcome of
these programs, including long-term adherence after DOT
completion, has not been determined (80–83).
Therapy Goals
Eradication of HIV infection cannot be achieved with avail-
able antiretroviral regimens, chiefly because the pool of la-
tently infected CD4+ T cells is established during the earliest
stages of acute HIV infection (84) and persists with a long
half-life, even with prolonged suppression of plasma viremia
to <50 copies/mL (85–88). The primary goals of antiretroviral
therapy are maximal and durable suppression of viral load,
restoration and preservation of immunologic function, im-
provement of quality of life, and reduction of HIV-related
morbidity and mortality (Table 10). In fact, adoption of treat-
ment strategies recommended in this report has resulted in
substantial reductions in HIV-related morbidity and mortal-
ity (89–91).
Plasma viremia is a strong prognostic indicator in HIV in-
fection (3). Furthermore, reductions in plasma viremia achieved
with antiretroviral therapy account for substantial clinical ben-
efits (92). Therefore, suppression of plasma viremia as much
as possible for as long as possible is a critical goal of
antiretroviral therapy, but this goal must be balanced against
the need to preserve effective treatment options. Switching
antiretroviral regimens for any detectable level of plasma vire-
mia can rapidly exhaust treatment options; reasonable param-
eters that can prompt a change in therapy are discussed in
Criteria for Changing Therapy.
HAART often leads to increases in the CD4+ T cell count
of >100–200 cells/mm3, although patient responses are vari-
able. CD4+ T cell responses are usually related to the degree of
viral load suppression (93). Continued viral load suppression
is more likely for those patients who achieve higher CD4+ T
cell counts during therapy (94). A favorable CD4+ T cell re-
sponse can occur with incomplete viral load suppression and
might not indicate an unfavorable prognosis (95). Durability
of the immunologic responses that occur with suboptimal
suppression of viremia is unknown; therefore, although viral
load is the strongest single predictor of long-term clinical out-
come, clinicians should consider also sustained rises in CD4+
T cell counts and partial immune restoration. The urgency of
changing therapy in the presence of low-level viremia is tem-
pered by this observation. Expecting that continuing the ex-
isting therapy will lead to rapid accumulation of drug-resistant
virus might not be reasonable for every patient. A reasonable
strategy is maintenance of the regimen, but with redoubled
efforts at optimizing adherence and increased monitoring.
Partial reconstitution of immune function induced by
HAART might allow elimination of unnecessary therapies (e.g.,
therapies used for prevention and maintenance against OIs).
The appearance of naïve T cells (96,97), partial normalization
of perturbed T cell receptor Vβ repertoires (98), and evidence
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of residual thymic function in patients receiving HAART
(99,100) demonstrate that partial immune reconstitution oc-
curs in these patients. Further evidence of functional immune
restoration is the return during HAART of in vitro responses
to microbial antigens associated with opportunistic infections
(101) and the lack of Pneumocystis carinii pneumonia among
patients who discontinued primary Pneumocystis carinii pneu-
monia prophylaxis when their CD4+ T cell counts rose to >200
cells/mm3 during HAART (102–104). Guidelines include rec-
ommendations concerning discontinuation of prophylaxis and
maintenance therapy for certain OIs when HAART-induced
increases in CD4+ T cell counts occur (2).
Tools for Achieving Therapy Goals
Although approximately 70%–90% of antiretroviral drug-
naïve patients achieve maximal viral load suppression 6–12
months after therapy initiation, only 50% of patients in cer-
tain city clinics achieved similar results (33,34). Predictors of
virologic success include low baseline viremia and high baseline
CD4+ T cell count (33–35), rapid decline of viremia (6), de-
cline of viremia to <50 HIV RNA copies/mL (6), adequate
serum levels of antiretroviral drugs (6,105), and adherence to
the drug regimen (34,51,106). Although optimal strategies
for achieving antiretroviral therapy goals have not been fully
delineated, efforts to improve patient adherence to therapy
are critical (see Adherence to Potent Antiretroviral Therapy).
Another tool for maximizing benefits of antiretroviral therapy
is the rational sequencing of drugs and the preservation of
future treatment options for as long as possible. Three alterna-
tive regimens include a protease inhibitor (PI) with two nucleo-
side reverse transcriptase inhibitors (NRTIs), a nonnucleoside
reverse transcriptase inhibitor (NNRTI) with two NRTIs, or
a 3-NRTI regimen (Table 11). The goal of a class-sparing regi-
men is to preserve or spare >1 classes of drugs for later use.
Extending the overall long-term effectiveness of the available
therapy options might be possible by sequencing drugs in this
manner. Moreover, this strategy enables selectively delaying
the risk for certain side effects associated with a single class of
drugs. The efficacy of PI-containing HAART regimens has
been reported to include durable viral load suppression, par-
tial immunologic restoration, and decreased incidence of AIDS
and death (24–26). Viral load suppression and CD4+ T cell
responses that are similar to those observed with PI-containing
regimens have been achieved with selected PI-sparing regimens
(e.g., efavirenz plus two NRTIs [107] or abacavir plus two
NRTIs [108]); however, whether such PI-sparing regimens will
provide comparable efficacy with regard to clinical outcomes
is unknown.
The presence of drug-resistant HIV among treatment-
experienced patients is a strong predictor of virologic failure
and disease progression (109–111). Results of prospective stud-
ies indicate that the virologic response to a new antiretroviral
regimen can be substantially improved when results of previ-
ous resistance testing are available to guide drug choices
(10,11). Thus, resistance testing is a useful tool in selecting
active drugs when changing antiretroviral regimens after viro-
logic failure (see Drug-Resistance Testing).
Initiating Therapy for the
Asymptomatic HIV-Infected Patient
When initiating antiretroviral therapy for the patient who is
naïve to such therapy, clinicians should begin with a regimen
that is expected to achieve sustained suppression of plasma
HIV RNA, a sustained increase in CD4+ T cell count, and a
favorable clinical outcome (i.e., delayed progression to AIDS
and death). Clinicians should consider also the regimen’s pill
burden, dosing frequency, food requirements, convenience,
toxicity, and drug-interaction profile compared with other regi-
mens. Strongly recommended regimens include either
indinavir, nelfinavir, ritonavir plus saquinavir; ritonavir plus
indinavir; ritonavir plus lopinavir; or efavirenz in combina-
tion with one of the two NRTI combinations (Table 12). Clini-
cal outcome data support using a PI in combination with
NRTIs (24–26) (BI). Ritonavir as the single PI should be con-
sidered as an alternative agent because certain patients have
difficulty tolerating standard doses of ritonavir (34) and be-
cause of the drug’s multiple interactions. A similar rationale
applies to saquinavir soft-gel capsule because certain patients
have difficulty tolerating standard doses and because of the
pill burden associated with its use; however, switching a pa-
tient off a ritonavir or saquinavir-based regimen is not neces-
sary if they are tolerating the regimen and it is effective.
Using ritonavir to increase plasma concentrations of other
PIs has evolved from an investigational concept to widespread
practice. Standard doses of PIs result in trough drug levels
(i.e., the lowest drug levels in the patient’s system) that are
only slightly higher than the effective antiviral concentration,
which could allow viral replication. In contrast, protease boost-
ing or enhancement by administering ritonavir increases the





minimizes opportunities for viral replication and potentially
allows drug activity against even moderately resistant strains
of virus. Additionally, these dual-PI combinations can lead to
more convenient regimens regarding pill burden, scheduling,
and elimination of food restrictions. They also might prevent
efavirenz- or nevirapine-induced drug interactions.
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**Additional information is available at http://www.hivatis.org.
Ritonavir increases plasma concentrations of other PIs by
>2 mechanisms, including inhibition of gastrointestinal cyto-
chrome P450 (CYP450) during absorption, and metabolic
inhibition of hepatic CYP450. The 20-fold increase in
saquinavir plasma concentrations with ritonavir
coadministration is probably caused by CYP450 inhibition at
both sites and leads to an increase in the saquinavir peak plasma
concentration (Cmax) (112). For lopinavir, the addition of
ritonavir increases the Cmax and half-life, which subsequently
results in a higher trough concentration. The result is a lopinavir
blood concentration curve that is 100-fold higher, compared
with lopinavir alone (113). For other PIs, metabolism in the
gastrointestinal tract is less critical, and the enhancement is
primarily the result of CYP450 inhibition in the liver. The
addition of ritonavir to amprenavir, nelfinavir, or indinavir
results in substantial increases in half-life and trough levels,
with a more moderate or minimal increase in Cmax (114,115).
The dose of ritonavir that is used for PI boosting is also
critical for certain PIs but not others. With saquinavir and
amprenavir, increases in the ritonavir dose to >100 mg two
times/day do not significantly increase the PI levels (114,116).
However, increasing ritonavir doses to >100 mg two times/
day provides additional enhancement for indinavir and
nelfinavir (115,117). Although pharmacokinetic data support
using ritonavir-plus-PI combinations, limited data are avail-
able regarding combinations other than ritonavir plus
saquinavir (118) or ritonavir plus lopinavir (119). In addi-
tion, the long-term risks and toxicities of dual-PI combina-
tions remain unknown.
Disappointing results with antiretroviral regimens prescribed
after virologic failure with a previous regimen indicate that
the first regimen affords the best opportunity for long-term
control of viral replication. Because the genetic barrier to re-
sistance is greatest with PIs, experienced clinicians consider a
PI plus two NRTIs to be the preferred initial regimen. How-
ever, efavirenz plus two NRTIs is as effective as one PI plus
two NRTIs in suppressing plasma viremia and increasing CD4+
T cell counts (107), and certain experienced clinicians prefer
this as the initial regimen because it might spare the toxicities
of PIs for a substantial time (BII). Although no direct com-
parative trials have been reported that would allow a ranking
of relative efficacy of NNRTIs, the ability of efavirenz in com-
bination with two NRTIs to suppress viral replication and
increase CD4+ T cell counts to a similar degree as one PI with
two NRTIs supports a preference for efavirenz over other pres-
ently available NNRTIs. Abacavir plus two NRTIs, a 3-NRTI
regimen, has been used successfully as well (108) (CII). How-
ever, such a regimen might have short-lived efficacy when the
baseline viral load is >100,000 copies/mL. Using two NRTIs
does not achieve the goal of suppressing viremia to below de-
tectable levels as consistently as does a regimen in the strongly
recommended or alternative categories and should be used
only if more potent treatment is impossible (DI). Use of
antiretroviral agents as monotherapy is contraindicated (DI),
except when no other options exist or during pregnancy to
reduce perinatal transmission. When initiating antiretroviral
therapy, all drugs should be started simultaneously at full dose
with the following exceptions: dose escalation regimens are
recommended for ritonavir, nevirapine, and for certain pa-
tients, ritonavir plus saquinavir.
Hydroxyurea has been used investigationally in combina-
tion with antiretroviral agents for treatment of HIV infection;
however, its utility in this setting has not been established.
Clinicians considering use of hydroxyurea in a treatment regi-
men for HIV should be aware of the limited and conflicting
nature of data in support of its efficacy and the importance of
monitoring patients closely for potentially serious toxicity.**
Detailed information is included in this report comparing
NRTIs, NNRTIs, PIs, drug interactions between PIs and other
agents, toxicities, and FDA-required warning labels (Tables
13–20). Drug interactions between PIs and other agents can
be extensive and often require dose modification or substitu-
tion of different drugs (Tables 17–19). Toxicity assessment is
an ongoing process; assessment >2 times during the first month
of therapy and every 3 months thereafter is a reasonable man-
agement approach.
Initiating Therapy for the Patient
with Advanced HIV Disease
All patients with diagnosed advanced HIV disease, which is
defined as any condition meeting the 1993 CDC definition
of AIDS (23), should be treated with antiretroviral agents,
regardless of plasma viral levels (AI). All patients with symp-
tomatic HIV infection without AIDS (i.e., the presence of
thrush or unexplained fever) should be treated also. When the
patient is acutely ill with an OI or other complication of HIV
infection, the clinician should consider clinical problems (e.g.,
drug toxicity, ability to adhere to treatment regimens, drug
interactions, or laboratory abnormalities) when determining
the timing of antiretroviral therapy initiation. When therapy
is initiated, a maximally suppressive regimen should be used
(Table 12). Advanced stage patients being maintained on an
antiretroviral regimen should not discontinue therapy during
an acute OI or malignancy, unless drug toxicity, intolerance,
or drug interactions are of concern.
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When patients who have progressed to AIDS are treated
with complicated combinations of drugs, potential multidrug
interactions must be appreciated by the clinician and patient.
Thus, when choosing antiretroviral agents, the clinician should
consider potential drug interactions and overlapping drug tox-
icities (Tables 13–20). For example, using rifampin to treat
active tuberculosis is problematic for a patient receiving a PI
that adversely affects the metabolism of rifampin but might
be needed to effectively suppress viral replication. Conversely,
rifampin lowers the blood level of PIs, which can result in
suboptimal antiretroviral therapy. Although rifampin is con-
traindicated or not recommended for use with all PIs, clini-
cians can consider using rifabutin at a reduced dose (Table
18); this topic is discussed in detail elsewhere (120). Other
factors complicating advanced disease are wasting and anor-
exia disorders, which can prevent patients from adhering to
the dietary requirements for efficient absorption of certain PIs.
Bone marrow suppression associated with zidovudine and the
neuropathic effects of zalcitabine, stavudine, and didanosine
can combine with the direct effects of HIV to render the drugs
intolerable. Hepatotoxicity associated with certain PIs and
NNRTIs can limit the use of these drugs (e.g., for patients
with underlying liver dysfunction). The absorption and half-
life of certain drugs can be altered by antiretroviral agents,
including PIs and NNRTIs whose metabolism involves
CYP450 enzymatic pathway. PIs inhibit the CYP450 path-
way, whereas NNRTIs have variable effects. Nevirapine is an
inducer; delavirdine is an inhibitor; and efavirenz is a mixed
inducer and inhibitor. CYP450 inhibitors can increase blood
levels of drugs metabolized by this pathway. Adding a CYP450
inhibitor can improve the pharmacokinetic profile of selected
agents (e.g., adding ritonavir therapy to saquinavir) as well as
contribute an antiviral effect; however, these interactions can
also result in life-threatening drug toxicity (Tables 11–19).
Thus, clinicians should discuss with their patients any new
drugs, including over-the-counter and alternative medications,
that the patient might consider taking. Relative risks versus
benefits of specific combinations of agents should be consid-
ered.
Initiation of potent antiretroviral therapy is associated with
degrees of immune function recovery. Patients with advanced
HIV disease and subclinical OIs (e.g., Mycobacterium avium-
intracellulare or cytomegalovirus) can experience a new im-
munologic response to the pathogen, and thus, new symptoms
can occur in association with the heightened immunologic or
inflammatory response. This response should not be interpreted
as an antiretroviral therapy failure, and these new OIs should
be treated appropriately while maintaining the patient on the
antiretroviral regimen. Viral load measurement is helpful in
clarifying the patient’s condition.
HAART-Associated Adverse
Clinical Events
Lactic Acidosis and Hepatic Steatosis
Chronic compensated hyperlactatemia can occur during
treatment with NRTIs (121,122). Although cases of severe
decompensated lactic acidosis with hepatomegaly and steato-
sis are rare (estimated incidence of 1.3 cases/1,000 person-
years of NRTI exposure), this syndrome is associated with a
high mortality rate (123–126). Severe lactic acidosis with or
without pancreatitis, including three fatal cases, were reported
during the later stages of pregnancy or among postpartum
women whose antiretroviral therapy during pregnancy included
stavudine and didanosine in combination with other
antiretroviral agents (125,127,128). Other risk factors for ex-
periencing this toxicity include obesity, being female, and pro-
longed use of NRTIs, although cases have been reported with
risk factors being unknown (125).
The mitochondrial basis of NRTI-induced lactic acidosis
and hepatic steatosis is one possible mechanism of cellular
injury because NRTIs also inhibit deoxyribonucleic acid
(DNA) polymerase gamma, which is the enzyme responsible
for mitochondrial DNA synthesis. The ensuing mitochondrial
dysfunction might also result in multiple other adverse events
(e.g., pancreatitis, peripheral neuropathy, myopathy, and car-
diomyopathy) (129). Certain features of lipodystrophy syn-
drome have been hypothesized as being tissue-specific
mitochondrial toxicities caused by NRTI treatment (130–132).
The initial clinical signs and symptoms of patients with lac-
tic acidosis syndrome are variable and can include nonspecific
gastrointestinal symptoms without substantial elevation of
hepatic enzymes (133). Clinical prodromes can include oth-
erwise unexplained onset and persistence of abdominal dis-
tention, nausea, abdominal pain, vomiting, diarrhea, anorexia,
dyspnea, generalized weakness, ascending neuromuscular weak-
ness, myalgias, paresthesias, weight loss, and hepatomegaly
(134). In addition to hyperlactatemia, laboratory evaluation
might reveal an increased anion gap (Na – [Cl + CO2] > 16),
elevated aminotransferases, creatine phosphokinase, lactic de-
hydrogenase, lipase, and amylase (124,133,135).
Echotomography and computed tomography (CT) scans
might indicate an enlarged fatty liver, and histologic examina-
tion of the liver might reveal microvesicular steatosis (133).
Because substantial technical problems are associated with lac-
tate testing, routine monitoring of lactate level is not usually
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recommended. Clinicians must first rely on other laboratory
abnormalities plus symptoms when lactic acidosis is suspected.
Measurement of lactate requires a standardized mode of sample
handling, including prechilled fluoride-oxalate tubes, which
should be transported immediately on ice to the laboratory
and processed within 4 hours after collection; blood should
be collected without using a tourniquet, without fist-clenching,
and if possible, without stasis (136,137). When interpreting
serum lactate, levels of 2–5 mmol/dL are considered elevated
and need to be correlated with symptoms. Levels >5 mmol/
dL are abnormal, and levels >10 mmol/dL indicate serious
and possibly life-threatening situations. Certain persons knowl-
edgeable in HIV treatment also recommend monitoring of
serum bicarbonate and electrolytes for the early identification
of an increased anion gap every 3 months.
For certain patients, the adverse event resolves after discon-
tinuation of NRTIs (133,138), and they tolerate administra-
tion of a revised NRTI-containing regimen (133,139);
however, insufficient data exist to recommend this strategy
versus treatment with an NRTI-sparing regimen. If NRTI treat-
ment is continued, for certain patients, progressive mitochon-
drial toxicity can produce severe lactic acidosis manifested
clinically by tachypnea and dyspnea. Respiratory failure can
follow, requiring mechanical ventilation. In addition to dis-
continuation of antiretroviral treatment and intensive thera-
peutic strategies that include bicarbonate infusions and
hemodialysis (140) (AI), clinicians can administer thiamine
(141) and riboflavin (127) on the basis of the pathophysi-
ologic hypothesis that sustained cellular dysfunctions of the
mitochondrial respiratory chain cause this fulminant clinical
syndrome. However, efficacy of these latter interventions re-
quires clinical validation. Antiretroviral treatment should be
suspended if clinical and laboratory manifestations of the lac-
tic acidosis syndrome occur (BIII).
Hepatotoxicity
Hepatotoxicity, which is defined as a 3–5 times increase in
serum transaminases (e.g., aspartate aminotransferase, alanine
aminotransferase, or gamma-glutamyltransferase) with or with-
out clinical hepatitis, has been reported among patients re-
ceiving HAART. All marketed NNRTIs and PIs have been
associated with serum transaminase elevation. The majority
of patients are asymptomatic, and certain cases resolve spon-
taneously without therapy interruption or modification (142).
Hepatic steatosis in the presence of lactic acidosis is a rare but
serious adverse effect associated with the nucleoside analogs
(see more detailed discussion in Lactic Acidosis and Hepatic
Steatosis).
Among the NNRTIs, nevirapine has the greatest potential
for causing clinical hepatitis. An incidence of 12.5% of hepa-
totoxicity among patients initiating nevirapine has been re-
ported, with clinical hepatitis diagnosed for 1.1% of these
patients (143). In an African randomized trial where stavudine
was the backbone NRTI, and either nevirapine or efavirenz
was added to emtricitabine or lamivudine, 9.4% of the
nevirapine-treated patients experienced grade 4 liver enzyme
elevation as compared with none of the efavirenz-treated pa-
tients. Two of these patients died of liver failure. The inci-
dence among female patients was twice that observed among
male patients (12% versus 6%; p = 0.05) (144). Nevirapine-
associated hepatitis might also be present as part of a hyper-
sensitivity syndrome, with a constellation of other symptoms
(e.g., skin rash, fever, and eosinophilia). Approximately two
thirds of the cases of nevirapine-associated clinical hepatitis
occur within the first 12 weeks. Fulminant and even fatal cases
of hepatic necrosis have been reported. Patients might experi-
ence nonspecific gastrointestinal and flu-like symptoms with
or without liver enzyme abnormalities. The syndrome can
progress rapidly to hepatomegaly, jaundice, and hepatic fail-
ure within days (145). A two-week lead-in dosing with 200
mg once daily before dose escalation to twice daily might re-
duce the incidence of hepatotoxicity. Because of the potential
severity of clinical hepatitis, certain clinicians advise close
monitoring of liver enzymes and clinical symptoms after
nevirapine initiation (e.g., every 2 weeks for the first month;
then monthly for first 12 weeks, and every 1–3 months there-
after). Patients who experience severe clinical hepatotoxicity
while receiving nevirapine should not receive nevirapine
therapy in the future.
Unlike the early onset hepatotoxicity observed with
nevirapine, PI-associated liver enzyme abnormalities can oc-
cur any time during the treatment course. In a retrospective
review, severe hepatotoxicity (defined as a >5 times increase
over baseline aspartate aminotransferase or alanine aminotrans-
ferase) was observed more often among patients receiving
ritonavir- or ritonavir/saquinavir-containing regimens than
those receiving indinavir, nelfinavir, or saquinavir (146).
Coinfection with hepatitis C virus is reported to be a major
risk factor for development of hepatotoxicity after PI initia-
tion (147,148). HAART-induced immune reconstitution
rather than direct liver toxic effects of the PIs have been indi-
cated as the cause of liver decompensation among hepatitis C
or hepatitis B coinfected patients. Other potential risk factors
for hepatotoxicity include hepatitis B infection (142,147,149),
alcohol abuse (148), baseline elevated liver enzymes (150),
stavudine use (149), and concomitant use of other hepato-
toxic agents.
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Hyperglycemia
Hyperglycemia, new-onset diabetes mellitus, diabetic ke-
toacidosis, and exacerbation of preexisting diabetes mellitus
have been reported among patients receiving HAART (151–
153). These metabolic derangements are strongly associated
with PI use (154), although they can occur independent of PI
use (155). The incidence of new onset hyperglycemia was re-
ported as 5% in a 5-year historical cohort analysis of a popu-
lation of 221 HIV-infected patients. PIs were independently
associated with hyperglycemia, and the incidence did not vary
substantially by PIs (156). Viral load suppression and increase
in body weight did not reduce the magnitude of the associa-
tion with PIs. The pathogenesis of these abnormalities has not
been fully elucidated; however, hyperglycemia might result
from peripheral and hepatic insulin resistance, relative insulin
deficiency, an impaired ability of the liver to extract insulin,
and a longer exposure to antiretroviral medications (157,158).
Hyperglycemia with or without diabetes has been reported
among 3%–17% of patients in multiple retrospective studies.
In these reports, symptoms of hyperglycemia were reported at
a median of approximately 60 days (range: 2–390 days) after
initiation of PI therapy. Hyperglycemia resolved for certain
patients who discontinued PI therapy; however, the reversibility
of these events is unknown because of limited data. Certain
patients continued PI therapy and initiated treatment with
oral hypoglycemic agents or insulin. Clinicians are advised to
monitor closely their HIV-infected patients with preexisting
diabetes when PIs are prescribed and to be aware of the risk
for drug-related new-onset diabetes among patients without a
history of diabetes (BIII). Patients should be advised regard-
ing the warning signs of hyperglycemia (i.e., polydipsia,
polyphagia, and polyuria) and the need to maintain a recom-
mended body weight when these medications are prescribed.
Certain clinicians recommend routine fasting blood glucose
measurements at 3–4-month intervals during the first year of
PI treatment for patients with no previous history of diabetes
(CIII). Routine use of glucose tolerance tests to detect this
complication is not recommended (DIII). Because pregnancy
is an independent risk factor for impaired glucose tolerance,
closer monitoring of blood glucose levels should be done for
pregnant women receiving PI-containing regimens. No data
are available to aid in the decision to continue or discontinue
drug therapy among patients with new-onset or worsening
diabetes; however, the majority of experienced clinicians rec-
ommend continuation of HAART in the absence of severe
diabetes (BIII). Studies have attempted to examine the poten-
tial of reversing insulin resistance after switching from PI-
containing HAART regimens to NNRTI-based regimens, but
results have been inconclusive.
Fat Maldistribution
HIV infection and antiretroviral therapy have been associ-
ated with unique fat distribution abnormalities. Generalized
fat wasting is common in advanced HIV disease, and local-
ized fat accumulations have been reported with NRTI
monotherapy (159). However, the recognition and observa-
tion of fat maldistribution syndromes have increased in the
era of combination antiretroviral therapy characterized by fat
wasting (lipoatrophy) or fat accumulation (hyperadiposity).
Fat maldistribution is often referred to as lipodystrophy, and
in combination with metabolic abnormalities including insu-
lin resistance and hyperlipidemia is referred to as lipodystro-
phy syndrome. The absence of a commonly used case definition
for the different forms of lipoatrophy or fat accumulation,
often collectively called lipodystrophy, has lead to different
prevalence estimates (range: 25%–75%) (160–163). Although
the lack of defining criteria has also impeded investigation
into the pathogenic mechanisms of these abnormalities, the
spectrum of morphologic abnormalities might indicate mul-
tifactorial causation related to specific antiretroviral exposure
and underlying host factors. Lipodystrophy might be associ-
ated with serum dyslipidemias, glucose intolerance, or lactic
acidosis (163–165).
Fat accumulation might be seen in the abdomen, the
dorsocervical fat pad, and, among both men and women, the
breasts. Prevalence increases with duration of antiretroviral
therapy (166). Although available evidence indicates that an
increased risk for fat accumulation exists with PIs, whether
specific drugs are more strongly associated with this toxicity is
unclear. The face and extremities are most commonly affected
by fat atrophy, and variability exists in severity. Prevalence of
this toxicity has been reported to increase with long-term NRTI
exposure (167). Although stavudine has been frequently re-
ported in cases of lipoatrophy, this might be a marker of longer
term treatment exposure (168–171).
No clearly effective therapy for fat accumulation or
lipoatrophy is known. In the majority of persons, discontinu-
ation of antiretroviral medications or class switching has not
resulted in substantial benefit; however, among a limited num-
ber of persons, improvement in physical appearance has been
reported (172). Preliminary results from limited studies indi-
cate a reduction in accumulated fat and fat redeposition with
the use of certain agents (personal communication, M.
Schambelan and P.A. Volberding, 2001) (173). However, data
are inconclusive and recommendations cannot be made.
Hyperlipidemia
HIV infection and antiretroviral therapy are associated with
complex metabolic alterations, including dyslipidemia.
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Cachexia, reduced total cholesterol, and elevated triglycerides
were reported before the availability of potent antiretroviral
therapy (174,175). HAART is associated with elevation of total
serum cholesterol and low-density lipoprotein and in addi-
tional increases in fasting triglycerides (162,176). The magni-
tude of changes varies substantially and does not occur among
all patients. Dyslipidemias primarily occur with PIs; however,
a range from an increased association with ritonavir to limited
or no association with a newer investigational compound in-
dicates that hyperlipidemia might be a drug-specific rather
than a class-specific toxicity (177).
Frequently, antiretroviral-associated dyslipidemias are suffi-
ciently severe enough to consider therapeutic intervention.
Although data remain inconclusive, lipid elevations might be
associated with accelerated atherosclerosis and cardiovascular
complications among HIV-infected persons.
Indications for monitoring and intervention in HIV therapy-
associated dyslipidemias are the same as among uninfected
populations (178). No evidence-based guidelines exist for lipid
management specific to HIV infection and antiretroviral
therapy. However, close monitoring of lipid levels among pa-
tients with additional risks for atherosclerotic disease might
be indicated (179). Low-fat diets, regular exercise, control of
blood pressure and smoking cessation are critical elements of
care. Hypercholesterolemia might respond to β-hdroxy-β-
methylglutaryl-CoA reductase inhibitors (statins). However,
recognizing the interactions of certain statins with PIs that
can result in increased statin levels is critical (Table 17). Usu-
ally, agents that are less affected by the inhibitory effect of PIs
via the cytochrome P450 system are preferred (e.g. pravastatin).
Atorvastatin, which is at least partially metabolized by this
pathway, can also be used with PIs. However, atorvastatin
should be used with caution and at reduced doses because
higher concentrations of atorvastatin are expected (180).
Monotherapy with fibrates is less effective, but they can be
added to statin therapy; additional monitoring is needed be-
cause of the increased risk of rhabdomyolysis and hepatotox-
icity. Isolated triglyceride elevations respond best to low-fat
diets, fibrates, or statins (180,181). Lipid elevations might
require modifications in antiretroviral regimens if they are se-
vere or unresponsive to other management strategies. Numer-
ous trials, variably well-controlled, have demonstrated modest
reductions in lipid elevations when an NNRTI replaces a PI
or when an abacavir-containing triple NRTI regimen replaces
a PI-containing regimen (182–184). Improvement in lipid
levels tends to be more substantial with nevirapine than with
efavirenz in studies regarding switching therapies.
Increased Bleeding Episodes
Among Patients with Hemophilia
Increased spontaneous bleeding episodes among patients
with hemophilia A and B have been observed with PI use (185).
Reported episodes have involved joints and soft tissues; how-
ever, serious bleeding episodes, including intracranial and gas-
trointestinal bleeding, have been reported. Bleeding episodes
occurred a median of 22 days after initiation of PI therapy.




Avascular necrosis and decreased bone density are now rec-
ognized as emerging metabolic complications of HIV infec-
tion that might be linked to HAART regimens. Both of these
bone abnormalities have been reported among adults and chil-
dren with HIV infection who are now surviving longer with
their disease in part because of HAART (186–188).
Avascular necrosis involving the hips was first described
among HIV-infected adults and more recently among HIV-
infected children (known as Legg-Calvé-Perthes disease). Di-
agnoses of osteonecrosis are usually made by CT scan or
magnetic resonance imaging (MRI), when these studies are
performed in response to patient’s complaints of pain in an
affected hip or spine. However, asymptomatic disease with
MRI findings can occur among 5% of HIV patients (189).
Avascular necrosis is not associated with a specific antiretroviral
regimen among HIV-infected adults, but it has been linked to
corticosteroids use among certain patients (189,190). Factors
associated with osteonecrosis include alcohol abuse, hemo-
globinopathies, corticosteroid treatment, hyperlipidaemia, and
hypercoagulability states. Occurrence of hyperlipidaemia in-
dicates an indirect link between antiretroviral therapy and the
occurrence of osteonecrosis among HIV-infected patients;
however, prospective clinical studies are required to establish
this association. No accepted medical therapy exists for avas-
cular necrosis, and surgery might be necessary for disabling
symptoms.
Decreases in bone mineral density (BMD), both moderate
(osteopenia) and severe (osteoporosis), are a reflection of the
competing effects of bone reabsorption by osteoclast and bone
deposition by osteoblast and are measured by bone densitom-
etry. Before HAART, marginal decreases in BMD among HIV-
infected persons were reported (191). This evidence for
decreased bone formation and turnover has been demonstrated
with more potent antiretroviral therapy, including PIs (192).
Studies of bone demineralization among a limited number of
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patients receiving HAART have reported that <50% of pa-
tients receiving a PI-based regimen experienced osteopenia,
compared with 20% of patients who are untreated or receiv-
ing a non-PI–containing regimen (193). Other studies have
reported that patients with lipodystrophy with extensive prior
PI therapy had associated findings of osteopenia (28%) or os-
teoporosis (9%), respectively (194). Preliminary observations
of increased serum and urinary markers of bone turnover
among patients on protease-containing HAART who have
osteopenia support the possible link of bone abnormalities to
other metabolic abnormalities observed among HIV-infected
patients (195,196). Presently, no recommendation can be made
for routine measurement of bone density among asymptom-
atic patients by dual energy X-ray absorptiometry (DEXA) or
by such newer measurements as quantitative ultrasound
(QUS). Specific prophylaxis or treatment recommendations
to prevent more substantial osteoporosis have not been devel-
oped for HIV-infected patients with osteopenia.
On the basis of experience in the treatment of primary os-
teoporosis, recommending adequate intake of calcium and
vitamin D and appropriate weight-bearing exercise is reason-
able. When fractures occur or osteoporosis is documented,
more specific and aggressive therapies with bisphosphonates,
raloxifene, or calcitonin might be indicated (197). Hormone
replacement therapy including estrogen can be considered in
the setting of substantially decreased bone density among post-
menopausal women on HAART.
Skin Rash
Skin rash occurs most commonly with the NNRTI class of
drugs. The majority of cases are mild to moderate, occurring
within the first weeks of therapy. Certain experienced clini-
cians recommend managing the skin rash with antihistamine
for symptomatic relief without drug discontinuation, although
continuing treatment during such rashes has been questioned
(198). More serious cutaneous manifestations (e.g., Stevens-
Johnson syndrome [SJS] and toxic epidermal necrosis [TEN])
should result in the prompt and permanent discontinuation
of NNRTI or other offending agents. The majority of reac-
tions resulting in skin rash are confined to cutaneous reac-
tions. However, a severe or even life-threatening syndrome of
drug rash with eosinophilia and systemic symptoms (DRESS)
has also been described (199,200). Systemic symptoms can
include fever, hematological abnormalities, and multiple or-
gan involvement. Among NNRTIs, skin rash occurs more fre-
quently and in greater severity with nevirapine. Using a 2-week
lead-in dose escalation schedule when initiating nevirapine
therapy might reduce the incidence of rash. In a case-control
multinational study, SJS and TEN were reported among 18
HIV-infected patients. Fifteen of the 18 patients were receiv-
ing nevirapine. The median time from initiation of nevirapine
to onset of cutaneous eruption was 11 days, with two thirds
of the cases occurring during the initial dosing period (198).
Female patients might have as much as a sevenfold higher risk
for developing grade 3 or 4 skin rashes than male patients
(201,202). The use of systemic corticosteroid or antihistamine
therapy at the time of the initiation of nevirapine to prevent
development of skin rash has not proven effective (202,203).
In fact, a higher incidence of skin rash has been reported among
the steroid- or antihistamine-treated patients. At present, pro-
phylactic use of corticosteroids should be discouraged.
Skin rash appears to be a class-adverse reaction of the
NNRTIs. The incidence of cross-hypersensitivity reactions
between these agents is unknown. In a limited number of re-
ports, patients with prior history of nevirapine-associated skin
rash had been able to tolerate efavirenz without increased rates
of cutaneous reactions (204,205). The majority of experienced
clinicians do not recommend using another NNRTI among
those patients who experienced SJS or TEN with one NNRTI.
Initiating NNRTI for a patient with a history of mild to mod-
erate skin rash with another NNRTI should be done with
caution and close follow-up.
Among the NRTIs, skin rash occurs most frequently with
abacavir. Skin rash might be one of the symptoms of abacavir-
associated systemic hypersensitivity reaction; in that case,
therapy should be discontinued without future attempts to
resume abacavir therapy.
Among all PIs, skin rash occurs most frequently with
amprenavir, with incidence of <27% in clinical trials. Although
amprenavir is a sulfonamide, the potential of cross-reactivity
between amprenavir and other sulfa drugs is unknown. As a
result, amprenavir should be used with caution in patients
with history of sulfa allergies.
Interruption
of Antiretroviral Therapy
Antiretroviral therapy might need to be discontinued tem-
porarily or permanently for multiple reasons. If a need exists
to discontinue any antiretroviral medication, clinicians and
patients should be aware of the theoretical advantage of stop-
ping all antiretroviral agents simultaneously, rather than con-
tinuing one or two agents, to minimize the emergence of
resistant viral strains. If a decision is made to interrupt therapy,
the patient should be monitored closely, including clinical and
laboratory evaluations. Chemoprophylaxis against OIs should
be initiated as needed on the basis of CD4+ T cell count.
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An interest exists in what is sometimes referred to as struc-
tured or supervised treatment interruptions (STI). The con-
cepts underlying STI vary, depending on patient populations,
and encompass >3 major strategies: 1) STI as part of salvage
therapy; 2) STI for autoimmunization and improved immune
control of HIV; and 3) STI for the sole purpose of allowing
less total time on antiretroviral therapy. Because of limited
available data, none of these approaches can be recommended.
Salvage STI is intended for patients whose virus has devel-
oped substantial antiretroviral drug resistance and who have
persistent plasma viremia and relatively low CD4+ T cell counts
despite receiving therapy. The theoretical goal of STI in this
patient population is to allow for the reemergence of HIV
that is susceptible to antiretroviral therapy. Although HIV that
was sensitive to antiretroviral agents was detected in the plasma
of persons after weeks or months of interrupted treatment,
the emergence of drug-sensitive HIV was associated with a
substantial decline in CD4+ T cells and a substantial increase
in plasma viremia, indicating improved replicative fitness and
pathogenicity of wild type virus (206). In addition, drug-
resistant HIV persisted in CD4+ T cells. The observed de-
crease in CD4+ T cells is of concern in this patient population,
and STI cannot be recommended for these patients.
Autoimmunization STI and STI for the reduction of total
time receiving antiretroviral drugs are intended for persons
who have maintained suppression of plasma viremia below
the limit of detection for prolonged periods of time and who
have relatively high CD4+ T cell counts. The theoretical goal
of autoimmunization STI is to allow multiple short bursts of
viral replication to augment HIV-specific immune responses.
This strategy is being studied among persons who began
HAART during either the very early or chronic stages of HIV
infection (207–209). STI for the purpose of less time on
therapy uses predetermined periods of long- or short-cycle
intermittent antiretroviral therapy. The numbers of patients
and duration of follow-up are insufficient for adequate evalu-
ation of these approaches. Risks include a decline in CD4+ T
cell counts, an increase in transmission, and the development
of drug resistance.
Because of insufficient data regarding these situations, STI
cannot be recommended for use in general clinical practice.
Further research is necessary in each of these areas.
Changing a Failing Regimen
As with the initiation of antiretroviral therapy, deciding to
change regimens should be approached after considering mul-
tiple, complex factors, including
• results of recent clinical history and physical examination;
• results of plasma HIV RNA levels, which have been mea-
sured on two occasions;
• absolute CD4+ T lymphocyte count and changes in these
counts;
• assessment of adherence to medications;
• remaining treatment options;
• potential resistance patterns from previous antiretroviral
therapies; and
• the patient’s understanding of the consequences of the
new regimen (e.g., side effects, drug interactions, dietary
requirements and possible need to alter concomitant medi-
cations).
A regimen can fail for multiple reasons, including among
other reasons, initial viral resistance to >1 agents, altered ab-
sorption or metabolism of the drug, multidrug pharmacoki-
netics that adversely affect therapeutic drug levels, and
inadequate patient adherence to a regimen. Careful assessment
of a patient’s adherence before changing antiretroviral therapy
is critical; the patient’s other health-care providers (e.g., the
case manager or social worker) can assist with this evaluation.
Clinicians should be aware of the prevalence of mental health
disorders and psychoactive substance use disorders among
HIV-infected persons because suboptimal mental health treat-
ment services can jeopardize the ability of these persons to
adhere to medical treatment. Optimal identification of and
intervention for these mental health disorders can enhance
adherence to HIV therapy.
Clinicians should distinguish between drug failure versus
drug toxicity before changing a patient’s therapy. In cases of
drug toxicity, >1 alternative drugs of the same potency and
from the same class of agents as the suspected agent should be
substituted. In cases of drug failure where >2 drugs have been
used, a detailed history of current and past antiretroviral medi-
cations, as well as other HIV-related medications, should be
obtained. Testing for antiretroviral drug resistance can also be
helpful in maximizing the number of active drugs in a regi-
men (see Drug-Resistance Testing). Viral resistance to
antiretroviral drugs can be a key reason for treatment failure.
Genetically distinct viral variants emerge in each HIV-infected
person after initial infection. Viruses with single-drug–resistant
mutations exist even before therapy but are selected for repli-
cation by antiviral regimens that are only partially suppres-
sive. The more potent a regimen is in durably suppressing HIV
replication, the less probable the emergence of resistant vari-
ants. Thus, a therapy’s goal should be to reduce plasma HIV
RNA to below detectable limits (i.e., <50 copies/mL), thereby
providing the strongest possible genetic barrier to drug resis-
tance.
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Three groups of patients should be considered for a change
in therapy: 1) persons who are receiving incompletely sup-
pressive antiretroviral therapy (e.g., single- or double-nucleoside
therapy) with detectable or undetectable plasma viral load; 2)
persons who have been on potent combination therapy and
whose viremia was initially suppressed to undetectable levels
but has again become detectable; and 3) persons who have
been on potent combination therapy and whose viremia was
never suppressed to below detectable limits.
Criteria for Changing Therapy
The goal of antiretroviral therapy, to improve the length
and quality of patients’ lives, is best accomplished by maximal
suppression of viral replication to below detectable levels (i.e.,
<50 copies/mL) sufficiently early to preserve immune func-
tion. However, to achieve this goal for certain patients, therapy
regimens must be modified. Plasma HIV RNA level is the key
parameter for evaluating therapy response, and increases in
levels of viremia that are substantial, confirmed, and not at-
tributable to intercurrent infection or vaccination, indicate
failure of the drug regimen regardless of changes in the CD4+
T cell counts. Clinical complications and sequential changes
in CD4+ T cell count can complement the viral load test in
evaluating a treatment response. Specific criteria that should
prompt consideration for changing therapy include the fol-
lowing:
• The patient experiences <0.5–0.75 log
10
 reduction in
plasma HIV RNA by 4 weeks after therapy initiation or
<1 log
10
 reduction by 8 weeks (CIII).
• Therapy fails to suppress plasma HIV RNA to undetect-
able levels within 4–6 months of initiation (BIII). The
degree of initial decrease in plasma HIV RNA and the
overall trend in decreasing viremia should be considered.
For example, a patient with 106 viral copies/mL before
therapy, who stabilizes after 6 months of therapy at an
HIV RNA level that is detectable but is <10,000 copies/
mL, might not warrant an immediate change in therapy.
• Virus in plasma is repeatedly detected after initial sup-
pression to undetectable levels, indicating resistance (BIII).
However, the degree of plasma HIV RNA increase should
be considered. Clinicians should consider short-term ob-
servation for a patient whose plasma HIV RNA increases
from undetectable to low-level detectability (e.g., 50–5,000
copies/mL) at 4 months. In this situation, the patient’s
health status should be followed closely. The majority of
patients who fall into this category will subsequently dem-
onstrate progressive increases in plasma viremia that will
probably require a change in the antiretroviral regimen.
• Any reproducible substantial increase, defined as >3-fold,
from the nadir of plasma HIV RNA that is not attribut-
able to intercurrent infection, vaccination, or test meth-
odology, except as noted previously (BIII).
• Undetectable viremia occurs in the patient receiving dual-
nucleoside therapy (BIII). Patients receiving two NRTIs
who have achieved no detectable virus have the option of
continuing this regimen or modifying it to conform to
regimens in the strongly recommended category
(Table 12). Previous experience indicates that patients on
dual-nucleoside therapy will eventually have virologic fail-
ure with a frequency that is substantially greater compared
with patients treated with the strongly recommended
regimens.
• CD4+ T cell numbers decline persistently, as measured on
>2 occasions (CIII).
• Clinical deterioration occurs (DIII). A new AIDS-defining
diagnosis that was acquired after treatment initiation in-
dicates clinical deterioration, but it might not indicate
failure of antiretroviral therapy. If the antiretroviral effect
of therapy was inadequate (e.g., <1.0 log
10
 fold reduction
in viral RNA), therapeutic failure might have occurred.
However, if the antiretroviral effect was adequate but the
patient was already severely immunocompromised, the
appearance of a new OI might not be an antiretroviral
therapy failure but a persistence of severe
immunocompromise that did not improve despite ad-
equate suppression of virus replication. Similarly, an ac-
celerated decline in CD4+ T cell counts indicates
progressive immune deficiency, if quality control of CD4+
T cell measurements has been ensured.
A final consideration is the recognition of the limited choice
of available agents and the knowledge that a decision to change
regimens might reduce future treatment options for that pa-
tient. This consideration can influence the clinician to be more
conservative when deciding to change therapy. Consideration
of alternative options should include potency of the substi-
tuted regimen and probability of tolerance of, or adherence
to, the alternative regimen. Clinical trials have demonstrated
that partial suppression of virus is superior to no suppression
of virus. Conversely, clinicians and patients might prefer to
suspend treatment to preserve future options or because a sus-
tained antiviral effect cannot be achieved. Referral to or con-
sultation with an experienced HIV clinician is appropriate
when considering a change in therapy. When possible, patients
requiring a change in antiretroviral regimen, but who are with-
out treatment options through using approved drugs, should
be referred for inclusion in a clinical trial.
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Therapeutic Options When Changing
Antiretroviral Therapy
Recommendations for changes in treatment differ accord-
ing to the indication for the change. If the desired virologic
objectives have been achieved for patients who have intoler-
ance or toxicity, a substitution for the offending drug should
be made, preferably by using an agent in the same class with a
different toxicity or tolerance profile. If virologic objectives
have been achieved, but the patient is receiving a regimen not
in the preferred category (e.g., two NRTIs or monotherapy),
treatment can be continued with careful monitoring of viral
load, or drugs can be added to the current regimen to comply
with strongly recommended treatment regimens. As previously
discussed, the majority of experienced clinicians believe that
treatment with regimens not in the strongly recommended or
alternative categories is associated with eventual failure, and
they recommend the latter tactic.
Limited clinical data exist to support specific strategies for
changing therapy among patients who have failed the strongly
recommended regimens; however, theoretical considerations
should guide decisions. Because of the rapid mutability of HIV,
viral strains with resistance to >1 agents can emerge during
therapy, chiefly when viral replication has not been maximally
suppressed. Of concern is the possibility of broad cross-
resistance among drugs within a class. Evidence indicates that
viral strains that become resistant to one PI or NNRTI often
have reduced susceptibility to the majority or all other PIs or
NNRTIs.
A change in regimen because of treatment failure should be
guided by results of resistance testing. This report includes a
summary of the guidelines to follow when changing a patient’s
antiretroviral therapy (Table 21). Dose modifications might
be necessary to account for drug interactions when using com-
binations of PIs or a PI and NNRTI (Table 19). For certain
patients, options are limited because of previous antiretroviral
use, toxicity, or intolerance. For the clinically stable patient
with detectable viremia for whom an optimal change in therapy
is not possible, delaying therapy changes in anticipation of
the availability of newer and more potent agents might be
prudent. Decisions to change therapy and design a new regi-
men should be made with assistance from a clinician well-
experienced in treating HIV-infected patients through
consultation or referral.
Acute HIV Infection
An estimated 40%–90% of patients acutely infected with
HIV will experience certain symptoms of acute retroviral syn-
drome (Table 22) and should be considered for early therapy
(210–213). However, acute HIV infection is often not recog-
nized by primary care clinicians because of the similarity of
the symptom complex with those of influenza or other ill-
nesses. Additionally, acute primary infection can occur
asymptomatically. Health-care providers should consider a
diagnosis of HIV infection for patients who experience a com-
patible clinical syndrome (Table 22) and should obtain ap-
propriate laboratory testing. Evidence includes detectable HIV
RNA in plasma by using sensitive PCR or bDNA assays com-
bined with a negative or indeterminate HIV antibody test.
Although measurement of plasma HIV RNA is the preferable
diagnostic method, a test for p24 antigen might be useful when
RNA testing is not readily available. However, a negative p24
antigen test does not eliminate acute infection, and a low titer
(<10,000 copies/mL), false-positive test can exist with HIV
RNA levels. When suspicion for acute infection is high (e.g.,
in a patient with a report of recent risk behavior in association
with the symptoms and signs listed in Table 22), a test for
HIV RNA should be performed (BII). Patients with diagnosed
HIV infection by HIV RNA testing should have confirma-
tory testing performed (Table 2).
Information regarding treatment of acute HIV infection
from clinical trials is limited. Preliminary data indicate that
treatment of primary HIV infection with combination therapy
has a beneficial effect on laboratory markers of disease pro-
gression (19,214–216). However, the potential disadvantages
of initiating therapy include additional exposure to
antiretroviral therapy without a known clinical benefit, which
could result in substantial toxicities, development of
antiretroviral drug resistance, and adverse effect on quality of
life. Ongoing clinical trials are addressing the question of long-
term benefits of potent treatment regimens. Theoretically, early
intervention can
• decrease the severity of acute disease;
• alter the initial viral setpoint, which can affect disease-
progression rates;
• reduce the rate of viral mutation as a result of suppression
of viral replication;
• preserve immune function; and
• reduce the risk for viral transmission.
The potential risks of therapy for acute HIV infection in-
clude
• adverse effects on quality of life resulting from drug tox-
icities and dosing constraints;
• drug resistance if therapy fails to effectively suppress viral
replication, which might limit future treatment options;
and
• a need for continuing therapy indefinitely.
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These considerations are similar to those for initiating
therapy for the asymptomatic patient (see Considerations for
Initiating Therapy for the Patient with Asymptomatic HIV-
Infection).
The health-care provider and the patient should be aware
that therapy of primary HIV infection is based on theoretical
considerations, and the potential benefits should be weighed
against the potential risks. Certain authorities endorse treat-
ment of acute HIV infection on the basis of the theoretical
rationale and limited but supportive clinical trial data.
Apart from patients with acute primary HIV infection, ex-
perienced clinicians also recommend consideration of therapy
for patients among whom seroconversion has occurred within
the previous 6 months (CIII). Although the initial burst of
viremia among infected adults usually resolves in 2 months,
treatment during the 2–6-month period after infection is based
on the probability that virus replication in lymphoid tissue is
still not maximally contained by the immune system during
this time (217). Decisions regarding therapy for patients who
test antibody-positive and who believe the infection is recent,
but for whom the time of infection cannot be documented,
should be made by using the algorithm discussed in Consid-
erations for Patients with Established HIV Infection (CIII).
Except for postexposure prophylaxis with antiretroviral agents
(218), no patient should be treated for HIV infection until
the infection has been documented. All patients being exam-
ined without a formal medical record of a positive HIV test
(e.g., those who have a positive result from a home test kit)
should undergo enzyme-linked immunosorbent assay and an
established confirmatory test (e.g., Western Blot) to document
HIV infection (AI).
Treatment Regimen for Primary
HIV Infection
After the clinician and patient have made the decision to
use antiretroviral therapy for primary HIV infection, treat-
ment should be implemented in an attempt to suppress plasma
HIV RNA levels to below detectable levels (AIII). Data are
insufficient to draw firm conclusions regarding specific drug
recommendations; potential combinations of agents available
are similar to those used in established infection (Table 12).
These aggressive regimens can be associated with disadvan-
tages, including drug toxicity, pill burden, cost, and the possi-
bility of drug resistance that could limit future options. The
latter is probable if virus replication is not adequately sup-
pressed or if the patient has been infected with a viral strain
that is already resistant to one or more agents. The patient
should be counseled regarding potential limitations, and de-
cisions should be made only after weighing the risks and se-
quelae of therapy against the theoretical treatment benefits.
Because 1) the goal of therapy is suppression of viral replica-
tion to below the level of detection; 2) the benefits of therapy
are based on theoretical considerations; and 3) long-term clini-
cal outcome benefit has not been documented, any regimen
that is not expected to maximally suppress viral replication is
not appropriate for treating the acutely HIV-infected person
(EIII). Additional clinical studies are needed to delineate the
role of antiretroviral therapy during the primary infection pe-
riod.
Patient Follow-Up
Testing for plasma HIV RNA levels and CD4+ T cell count
and toxicity monitoring should be performed as described in
Testing for Plasma HIV RNA Levels and CD4+ T Cell Count
To Guide Decisions Regarding Therapy (i.e., on initiation of
therapy, after 4 weeks, and every 3–4 months thereafter) (AII).
However, certain experienced clinicians believe that testing
for plasma HIV RNA levels at 4 weeks is not helpful in evalu-
ating the therapy’s effect regarding acute infection, because
viral loads might be decreasing from peak viremia levels, even
in the absence of therapy.
Duration of Therapy for Primary
HIV Infection
After therapy is initiated, experienced clinicians recommend
continuing treatment with antiretroviral agents indefinitely
because viremia has been documented to reappear or increase
after therapy discontinuation (CII). Optimal duration and
therapy composition are unknown, but ongoing clinical trials
should provide relevant data regarding these concerns. Diffi-
culties inherent in determining the optimal duration and
therapy composition initiated for acute infection should be




HIV-infected adolescents who were infected through sex or
injection-drug use during adolescence follow a clinical course
that is more similar to HIV disease among adults than chil-
dren. In contrast, adolescents who were infected perinatally or
through blood products as young children have a unique clini-
cal course that differs from other adolescents and long-term
surviving adults. The majority of HIV-infected adolescents
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were infected through sex during the adolescent period and
are in an early stage of infection.
Puberty is a time of somatic growth and hormone-mediated
changes, with females acquiring additional body fat and males
additional muscle mass. Theoretically, these physiologic
changes can affect drug pharmacology, including drugs with a
narrow therapeutic index that are used in combination with
protein-bound medicines or hepatic enzyme inducers or in-
hibitors. However, no clinically substantial impact of puberty
has been reported with NRTI use. Clinical experience with
PIs and NNRTIs has been limited. Thus, medication dosages
used to treat HIV and OIs among adolescents should be based
on Tanner staging of puberty and not specific age. Adoles-
cents in early puberty (Tanner stages I and II) should be ad-
ministered dosages on the basis of pediatric guidelines, whereas
those in late puberty (Tanner stage V) should be administered
dosages on the basis of adult guidelines. Youth who are in the
midst of their growth spurt (Tanner stage III females and Tan-
ner stage IV males) should be monitored closely for medica-





Antiretroviral treatment recommendations for HIV-infected
pregnant women are based on the belief that therapies of known
benefit to women should not be withheld during pregnancy,
unless the risk for adverse effects outweighs expected benefits
for the woman. Combination antiretroviral therapy is the rec-
ommended standard treatment for HIV-infected nonpregnant
women. Additionally, a three-part regimen of zidovudine, ad-
ministered orally starting at 14 weeks gestation and contin-
ued throughout pregnancy, intravenously during labor and to
the newborn for the first 6 weeks of life, reduced the risk for
perinatal transmission by 66% in a randomized, double-blind
clinical trial (i.e., the Pediatric AIDS Clinical Trials Group
[PACTG] protocol 076) (20) and is recommended for all preg-
nant women (219). Pregnancy should not preclude the use of
optimal therapeutic regimens. However, recommendations
regarding choices of antiretroviral drugs for treatment of in-
fected women are subject to unique considerations including
1) potential changes in dosing requirement resulting from
physiologic changes associated with pregnancy, 2) potential
effects of antiretroviral drugs on a pregnant woman, 3) effect
on the risk for perinatal HIV transmission, and 4) the poten-
tial short- and long-term effects of the antiretroviral drug on
the fetus and newborn, all of which might not be known for
certain antiretroviral drugs (219). The decision to use any
antiretroviral drug during pregnancy should be made by the
woman after discussion with her clinician regarding the ben-
efits versus risks to her and her fetus. Long-term follow-up is
recommended for all infants born to women who have re-
ceived antiretroviral drugs during pregnancy.
Women who are in the first trimester of pregnancy and who
are not receiving antiretroviral therapy might wish to consider
delaying therapy initiation until after 10–12 weeks gestation.
This period of organogenesis is when the embryo is most sus-
ceptible to potential teratogenic drug effects, and the risks re-
garding antiretroviral therapy to the fetus during that period
are unknown. However, this decision should be discussed be-
tween the clinician and patient and should include an assess-
ment of the woman’s health status and the benefits versus risks
of delaying therapy initiation for these weeks. If clinical, viro-
logic, or immunologic parameters are such that therapy would
be recommended for nonpregnant women, the majority of
Panel members recommend initiating therapy regardless of
gestational age. Nausea and vomiting during early pregnancy,
affecting the woman’s ability to take and absorb oral medica-
tions, can be a factor in the decision regarding treatment dur-
ing the first trimester.
Standard combination antiretroviral therapy is recommended
as initial therapy for HIV-infected pregnant women whose
clinical, immunologic, or virologic status would indicate treat-
ment if not pregnant. When antiretroviral therapy initiation
would be considered optional on the basis of current guide-
lines for treatment of nonpregnant women, but HIV-1 RNA
levels are >1,000 copies/mL, infected pregnant women should
be counseled regarding the benefits of standard combination
therapy and offered therapy, including the three-part
zidovudine chemoprophylaxis regimen (Table 23). Although
such women are at low risk for clinical disease progression if
combination therapy is delayed, antiretroviral therapy that
successfully reduces HIV-1 RNA levels to <1,000 copies/mL
substantially lowers the risk for perinatal transmission (220–
222) and limits the need to consider elective cesarean delivery
as an intervention to reduce transmission risk (219).
Use of antiretroviral prophylaxis has been demonstrated to
provide benefit in preventing perinatal transmission, even for
infected pregnant women with HIV-1 RNA levels <1,000
copies/mL. In a meta-analysis of factors associated with peri-
natal transmission among women who had infected infants
despite having HIV-1 RNA <1,000 copies/mL at or near de-
livery, transmission was only 1.0% among women receiving
zidovudine prophylaxis compared with 9.8% among those
receiving no antiretroviral treatment (220). The time-limited
use of zidovudine alone during pregnancy for chemoprophy-
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†† Additional information is available at http://www.hivatis.org.
laxis of perinatal transmission is controversial. Potential ben-
efits of standard combination antiretroviral regimens for treat-
ment of HIV infection should be discussed with and offered
to all pregnant HIV-infected women regardless of viral load
and is recommended for all pregnant women with HIV-1 RNA
levels >1,000 copies/mL. However, a woman might wish to
restrict exposure of her fetus to antiretroviral drugs during
pregnancy but still wish to reduce the risk for transmitting
HIV to her infant. Additionally, for women with HIV-1 RNA
levels <1,000 copies/mL, time-limited use of zidovudine dur-
ing the second and third trimesters of pregnancy is less likely
to induce resistance caused by the limited viral replication ex-
isting in the patient and the time-limited exposure to the
antiretroviral drug. For example, zidovudine resistance was
unusual among healthy women who participated in PACTG
076 (21). Use of zidovudine chemoprophylaxis alone during
pregnancy might be an appropriate option for these women.
When combination therapy is administrated principally to
reduce perinatal transmission and would have been consid-
ered optional for treatment if the woman were not pregnant,
consideration can be given to discontinuing therapy postna-
tally, with the decision to reinstitute treatment on the basis of
standard criteria for nonpregnant women. If drugs are discon-
tinued postnatally, all drugs should be stopped simultaneously.
Discussion regarding the decision to continue or stop combi-
nation therapy postpartum should occur before initiation of
therapy during pregnancy.
Women already receiving antiretroviral therapy might rec-
ognize their pregnancy early enough in gestation that concern
for potential teratogenicity can lead them to consider tempo-
rarily stopping antiretroviral therapy until after the first tri-
mester. Insufficient data exist to support or refute teratogenic
risk regarding antiretroviral drug use among humans when
administered during the first 10–12 weeks of gestation. How-
ever, treatment with efavirenz should be avoided during the
first trimester because substantial teratogenic effects among
rhesus macaques occurred at drug exposures similar to those
representing human exposure. Hydroxyurea is a potent ter-
atogen among animal species and should be avoided also dur-
ing the first trimester.
Temporary discontinuation of antiretroviral therapy could
result in a rebound in viral levels that theoretically could be
associated with increased risk for early in utero HIV transmis-
sion or could potentiate disease progression in the woman
(223). Although the effects of all antiretroviral drugs on the
developing fetus during the first trimester are uncertain, expe-
rienced clinicians recommend continuation of a maximally
suppressive regimen, even during the first trimester. If
antiretroviral therapy is discontinued during the first trimes-
ter for any reason, all agents should be stopped simultaneously
to avoid drug resistance. After the drugs are reinstituted, they
should be introduced simultaneously for the same reason.
Limited data are available on the pharmacokinetics and safety
of antiretroviral agents during pregnancy for drugs other than
zidovudine.†† In the absence of data, drug choices should be
personalized on the basis of discussion with the patient and
available data from preclinical and clinical testing of each drug.
FDA’s pregnancy classification for all currently approved
antiretroviral agents and selected other information regarding
the use of antiretroviral drugs is available in this report (Table
24).The predictive value of in vitro and animal screening tests
for adverse effects among humans is unknown. Certain drugs
commonly used to treat HIV infection or its consequences
can result in positive readings on >1 screening tests. For ex-
ample, acyclovir is positive on certain in vitro assays for chro-
mosomal breakage and carcinogenicity and is associated with
fetal abnormalities among rats; however, data regarding hu-
man experience from the Acyclovir in Pregnancy Registry in-
dicate no increased risk for birth defects among human infants
with in utero exposure (224).
When combination antiretroviral therapy is administered
during pregnancy, zidovudine should be included as a com-
ponent of antenatal therapy whenever possible. Circumstances
might arise where this option is not feasible (e.g., occurrence
of substantial zidovudine-related toxicity). Additionally,
women receiving an antiretroviral regimen that does not con-
tain zidovudine but who have HIV-1 RNA levels that are con-
sistently low or undetectable have a low risk for perinatal
transmission, and addition of zidovudine to the current regi-
men could compromise regimen adherence. Regardless of the
antepartum antiretroviral regimen, intravenous intrapartum
zidovudine and the standard 6-week course of zidovudine for
the infant is recommended. If the woman has not received
zidovudine as a component of her antenatal therapeutic
antiretroviral regimen, intravenous zidovudine should still be
administered to the pregnant woman during the intrapartum
period, when feasible. Additionally, for women receiving com-
bination antiretroviral treatment, the maternal antenatal
antiretroviral treatment regimen should be continued on sched-
ule as much as possible during labor to provide maximal viro-
logic effect and to minimize the chance of drug resistance.
Zidovudine and stavudine should not be administered together
because of potential pharmacologic antagonism; therefore,
options for women receiving oral stavudine as part of their
antenatal therapy include continuing oral stavudine during
labor without intravenous zidovudine or withholding oral
stavudine during intravenous administration during labor.
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Toxicity related to mitochondrial dysfunction has been re-
ported among HIV-infected patients receiving long-term treat-
ment with nucleoside analogues and can be of concern for
pregnant women. Symptomatic lactic acidosis and hepatic ste-
atosis can have a female preponderance (125). Additionally,
these syndromes have similarities to the rare but life-threatening
syndromes of acute fatty liver of pregnancy and hemolysis,
elevated liver enzymes and low platelets (HELLP syndrome)
that occur during the third trimester of pregnancy. Certain
data indicate that a disorder of mitochondrial fatty acid oxi-
dation in the mother or her fetus during late pregnancy can
affect the etiology of acute fatty liver of pregnancy and HELLP
syndrome (225,226) and possibly contribute to susceptibility
to antiretroviral-associated mitochondrial toxicity.
Whether pregnancy augments the incidence of the lactic
acidosis/hepatic steatosis syndrome reported among nonpreg-
nant women receiving nucleoside analogue treatment is un-
clear. Bristol-Myers Squibb has reported three maternal deaths
caused by lactic acidosis, two with and one without accompa-
nying pancreatitis, among women who were either pregnant
or postpartum and whose antepartum therapy during preg-
nancy included stavudine and didanosine in combination with
other antiretroviral agents (either a PI or nevirapine) (128).
All cases were among women who were receiving treatment
with these agents at the time of conception and continued for
the duration of pregnancy; all of the women were seen late in
gestation with symptomatic disease that progressed to death
in the immediate postpartum period. Two women were also
associated with fetal demise. Nonfatal cases of lactic acidosis
among pregnant women have also been reported.
Because pregnancy itself can mimic certain early symptoms
of lactic acidosis/hepatic steatosis syndrome or be associated
with other disorders of liver metabolism, clinicians who care
for HIV-infected pregnant women receiving nucleoside ana-
logue drugs need to be alert for this syndrome. Pregnant women
receiving nucleoside analogue drugs should have hepatic en-
zymes and electrolytes assessed more frequently during the last
trimester of pregnancy, and any new symptoms should be
evaluated thoroughly. Additionally, because of reports of ma-
ternal mortality secondary to lactic acidosis with prolonged
use of the combination of stavudine and didanosine by HIV-
infected pregnant women, clinicians should prescribe this
antiretroviral combination during pregnancy with caution and
only when other nucleoside analogue drug combinations have
failed or caused unacceptable toxicity or side effects (128).
The antenatal zidovudine dosing regimen used in the peri-
natal transmission prophylaxis trial PACTG 076 was
zidovudine 100 mg administered five times/day and was se-
lected on the basis of standard zidovudine dosage for adults at
the time the study was designed in 1989 (Table 23). However,
data indicate that administration of zidovudine three times/
day will maintain intracellular zidovudine triphosphate at lev-
els comparable with those observed with more frequent dos-
ing (227,228). Comparable clinical response also has been
observed in clinical trials among persons receiving zidovudine
two times/day (229–231). Thus, the standard zidovudine dos-
ing regimen for adults is 200 mg three times/day or 300 mg
two times/day. A less-frequent dosing regimen would be ex-
pected to enhance maternal adherence to the zidovudine peri-
natal prophylaxis regimen and, therefore, is an acceptable
alternative antenatal dosing regimen for zidovudine prophy-
laxis.
In a short-course antenatal/intrapartum zidovudine perina-
tal transmission prophylaxis trial in Thailand, administration
of zidovudine 300 mg two times/day for 4 weeks antenatally
and 300 mg every 3 hours orally during labor was reported to
reduce perinatal transmission by approximately 50%, com-
pared with a placebo (232). The lower efficacy of the short-
course two-part zidovudine prophylaxis regimen studied in
Thailand compared with the three-part zidovudine prophy-
laxis regimen used in PACTG 076 and recommended for use
in the United States, could result from 1) the shorter antena-
tal duration of zidovudine, 2) oral rather than intravenous
administration during labor, 3) lack of treatment for the in-
fant, or 4) a combination of these factors. In the United States,
identification of HIV-infected pregnant women before or as
early as possible during the course of pregnancy and use of the
full three-part PACTG 076 zidovudine regimen is recom-
mended for prevention of perinatal HIV transmission.
Monitoring and use of HIV-1 RNA for therapeutic
decision-making during pregnancy should be performed as
recommended for nonpregnant women. Data from untreated
and zidovudine-treated infected pregnant women indicate that
HIV-1 RNA levels correlate with risk for transmission
(20,221,222). However, although risk for perinatal transmis-
sion among women with HIV-1 RNA below the level of assay
quantitation is low, transmission from mother to infant has
been reported among women with all levels of maternal HIV-1
RNA. Additionally, antiretroviral prophylaxis is effective in
reducing transmission even among women with low HIV RNA
levels (20,220). Although the mechanism by which
antiretroviral prophylaxis reduces transmission is probably
multifactorial, reduction in maternal antenatal viral load is a
key component of prophylaxis. However, pre- and postexposure
prophylaxis of the infant is provided by passage of antiretroviral
drugs across the placenta, resulting in inhibitory drug levels in
the fetus during and immediately after the birth process (233).
The extent of transplacental passage varies among antiretroviral
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drugs (Table 24). Additionally, although a correlation exists
between plasma and genital tract viral load, discordance has
also been reported (234–236). Further, differential evolution
of viral sequence diversity occurs between the peripheral blood
and genital tract (236,237). Studies are needed to define the
relationship between viral load suppression by antiretroviral
therapy in plasma and levels of HIV in the genital tract and
the relationship between these compartment-specific effects
and the risk for perinatal HIV transmission. The full
zidovudine chemoprophylaxis regimen, including intravenous
zidovudine during delivery and zidovudine administration to
the infant for the first 6 weeks of life, in combination with
other antiretrovirals or alone, should be discussed with and
offered to all infected pregnant women regardless of their
HIV-1 RNA level.
Clinicians who are treating HIV-infected pregnant women
are strongly encouraged to report cases of prenatal exposure to
antiretroviral drugs (either administered alone or in combina-
tions) to the Antiretroviral Pregnancy Registry. The registry
collects observational, nonexperimental data regarding
antiretroviral exposure during pregnancy for the purpose of
assessing potential teratogenicity. Registry data will be used to
supplement animal toxicology studies and assist clinicians in
weighing the potential risks and benefits of treatment for each
patient. The registry is a collaborative project with an advi-
sory committee of obstetric and pediatric practitioners, staff
from CDC and NIH, and staff from pharmaceutical manu-
facturers. The registry allows the anonymity of patients, and
birth outcome follow-up is obtained by registry staff from the
reporting clinician. Referrals should be directed to
Antiretroviral Pregnancy Registry
115 North Third Avenue, Suite 306,
Wilmington, NC 28401
Telephone: 910-251-9087 or 1-800-258-4263
FAX: 1-800-800-1052
Prevention Counseling
for the HIV-Infected Patient
Ongoing prevention counseling is an essential component
of management for HIV-infected persons (238). Each patient
encounter provides an opportunity to reinforce HIV preven-
tion messages. Therefore, each encounter should include as-
sessment and documentation of 1) the patient’s knowledge
and understanding of HIV transmission and 2) the patient’s
HIV transmission behaviors since the last encounter with a
member of the health-care team. This should be followed by a
discussion of strategies to prevent transmission that might be
useful to the patient. The physician, nurse, or other health-
care team member should routinely provide this counseling.
Partner notification is a key component of HIV detection and
prevention and should be pursued by the provider or by refer-
ral services.
Although the core elements of HIV prevention messages are
unchanged since the introduction of HAART, key observa-
tions regarding the biology of HIV transmission, the impact
of HAART on transmission, and personal risk behaviors have
been noted. For example, sustained low plasma viremia that
results from successful HIV therapy substantially reduces the
likelihood of HIV transmission. In one study, for each log
reduction in plasma viral load, the likelihood of transmission
between discordant couples was reduced 2.5-fold (239). Simi-
larly, mother-to-child HIV transmission was observed to de-
cline in a linear fashion with each log reduction in maternal
delivery viral load (221,222,238,239). Although this relation-
ship is usually linear, key exceptions should be noted. For ex-
ample, mother-to-child transmission has been reported even
among women with very low or undetectable viral loads
(220,240,241). Similarly, the relationship between viral load
in the plasma and the levels in the genital fluid of women and
the seminal fluid of men is complex. Studies have demon-
strated a rough correlation between plasma HIV levels and
genital HIV levels, but key exceptions have been observed
(240). Viral evolution can occur in the genital compartment
that is distinct from the viral evolution in the plasma, and
transmissions have been documented in the presence of an
undetectable plasma viral load (20,220,241). Thus, although
durably effective HAART substantially reduces the likelihood
of HIV transmission, the degree of protection is incomplete.
Certain biologic factors other than plasma viral load have
also been demonstrated to influence sexual transmission of
HIV, including ulcerative and nonulcerative sexually trans-
mitted infections (242), vaginitis (including bacterial vaginosis
and Candida albicans vaginal infections) (243); genital irrita-
tion associated with frequent use of nonoxynol-9 (N-9)–
containing products (244); menstruation; lack of circumcision
in men (245–247); oral contraceptive use (248); estrogen de-
ficiency (248); progesterone excess (243); and deficiencies of
vitamin A (249) and selenium (247).
Behavioral changes among HIV-infected persons have been
observed during the HAART era that impact prevention.
Unfortunately, evidence exists that awareness of the potential
benefits of HAART is leading certain persons to relapse into
high-risk activities. For example, reports from urban commu-
nities of men who have sex with men (MSM) in the United
States indicate rising HIV seroprevalence rates, as well as ris-
ing rates of unsafe sexual practices, corroborated by the rising
rates of other sexually transmitted infections. Recently, an as-
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sociation between knowledge of the benefits of HAART among
MSM and relapse to high-risk activity was observed (250,251).
Women might have unprotected sex because they wish to
become pregnant. For women of childbearing potential, de-
sire for pregnancy should be assessed at each encounter; women
wishing to pursue pregnancy should be referred for precon-
ception counseling to reduce risks for perinatal transmission
and transmission to uninfected sexual partners. Among women
of childbearing age who wish to avoid pregnancy, condoms
should be encouraged in addition to other forms of contra-
ception for preventing transmission of HIV and other sexu-
ally transmitted infections (dual method use) or used as a single
method for pregnancy prevention as well (dual protection). In
a randomized placebo-controlled clinical trial of N-9 con-
ducted among commercial sex workers with high rates of sexual
activity, N-9 did not protect against HIV infection, resulted
in increased vaginal lesions, and possibly caused increased trans-
mission (243). Although these adverse effects might not oc-
cur with less frequent use, given current evidence, spermicides
containing N-9 should not be recommended as an effective
means of HIV prevention.
Optimal adherence with antiretroviral regimens has been
directly associated with a lower risk for morbidity and mortal-
ity and indirectly with a reduction in risk for HIV transmis-
sion because of its association with lower viral loads (252).
Suboptimal adherence to HIV medication recently has been
demonstrated to be a predictor of suboptimal adherence to
HIV prevention strategies (253). More intensive adherence
and prevention counseling might be appropriate for persons
who demonstrate repeated deficiencies in either area.
Despite the strong association between a reduced risk for
HIV transmission and sustained low viral load, the message
of HIV prevention for patients should remain simple: After
becoming infected, a person can transmit the virus at any time,
and no substitute exists for latex or polyurethane male or fe-
male condoms, other safer sexual behaviors (e.g., partner re-
duction or abstinence), and cessation of any sharing of drug
paraphernalia. Prevention counseling for patients known to
have HIV infection remains a critical component of HIV pri-
mary care, including easy access to condoms and other means
of prevention. Clinicians might wish to directly address with
their patients the risks associated with using viral load out-
comes as a factor in considering high-risk behavior. HIV-
infected persons who use injection drugs should be advised to
enroll in drug rehabilitation programs. If this advice is not
followed or if these services are unavailable, the patient should
receive counseling regarding risks associated with sharing
needles and paraphernalia.
Finally, the most successful and effective prevention mes-
sages are those tailored to each patient. These messages are
culturally appropriate, practical, and relevant to the person’s
knowledge, beliefs, and behaviors (238). The message, the
manner of delivery, and the cultural context vary substantially,
depending on the patient (for additional information regard-
ing these strategies, as well as recommendations on preven-
tion, see HIV Prevention at http://hivinsite.ucsf.edu/
InSite.jsp?page=kb-07).
Conclusion
The Panel has attempted to use the advances in knowledge
regarding the pathogenesis of HIV in the infected person to
translate scientific principles and data obtained from clinical
experience into guidelines that can be used by clinicians and
patients to make therapeutic decisions. These guidelines are
offered for ongoing discussion between the patient and clini-
cian after having defined specific therapeutic goals with an
acknowledgment of uncertainties. Patients should be entered
into a continuum of medical care and services, including so-
cial, psychosocial, and nutritional services, with the availabil-
ity of professional referral and consultation. To achieve the
maximal flexibility in tailoring therapy to each patient during
his or her infection, drug formularies must allow for all FDA-
approved NRTIs, NNRTIs, and PIs as treatment options. The
Panel urges industry and the public and private sectors to con-
duct further studies to allow refinement of these guidelines.
Specifically, studies are needed to optimize recommendations
for primary therapy; to define secondary therapy; and to de-
lineate the reasons for treatment failure. The Panel remains
committed to revising these guidelines as new data become
available.
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FIGURE. Liklihood of developing acquired immunodeficiency
syndrome by 3 years after becoming infected with human
immunodeficiency virus
* b-Deoxynbonucleic acid.
† Reverse transcriptase-polymerase chain reaction.
Source: Mellors JW, Muñoz A, Gigorgi JV, et al. Plasma viral load and
CD4
+
 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern
Med 1997;126:946–54.
TABLE 1. Rating scheme for clinical practice recommendations
Category Definition
Strength of recommendation
A Strong; should always be offered
B Moderate; should usually be offered
C Optional
D Should usually not be offered
E Should never be offered
Quality of evidence for recommendation
I At least one randomized trial with clinical results
II Clinical trials with laboratory results
III Expert opinion
TABLE 2. Indications for plasma human immunodeficiency virus (HIV) ribonucleic acid (RNA) testing*
Clinical indication Information Use
Syndrome consistent with acute HIV Establishes diagnosis when HIV antibody test Diagnosis†
infection is negative or indeterminate
Initial evaluation of newly diagnosed HIV Baseline viral load setpoint Decision to start or defer therapy
infection
Every 3–4 months for patients not on therapy Changes in viral load Decision to start therapy
2–8 weeks after initiation of antiretroviral Initial assessment of drug efficacy Decision to continue or change therapy
therapy
3–4 months after start of therapy Maximal effect of therapy Decision to continue or change therapy
Every 3–4 months for patients on therapy Durability of antiretroviral effect Decision to continue or change therapy
Clinical event or substantial decline in Association with changing or stable viral load Decision to continue, initiate, or change therapy
CD4+ T cells
* Acute illness (e.g., bacterial pneumonia, tuberculosis, herpes simplex virus, or Pneumocystis carinii pneumonia) and vaccinations can cause an increase
in plasma HIV RNA for 2–4 weeks; viral load testing should not be performed during this time. Plasma HIV RNA results should be verified with a repeat
determination before starting or changing therapy.
†
Diagnosis of HIV infection on the basis of HIV RNA testing should be confirmed by standard methods (e.g., Western blot serology performed 2–4 months
after the initial indeterminate or negative test).
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TABLE 3. Recommendations for using drug-resistance assays
Clinical setting/recommendations Rationale
Drug-resistance assay recommended
Virologic failure during highly active antiretroviral therapy Determine the role of resistance in drug failure and maximize the number
of active drugs in the new regimen, if indicated
Suboptimal suppression of viral load after antiretroviral therapy Determine the role of resistance and maximize the number of active drugs
initiation in the new regimen, if indicated
Drug-resistance assay should be considered
Acute human immunodeficiency virus (HIV) infection Determine if drug-resistant virus was transmitted and change regimen
accordingly
Drug-resistance assay not usually recommended
Chronic HIV infection before therapy initiation Uncertain prevalence of resistant virus; available assays might not detect
minor drug-resistant species
After discontinuation of drugs Drug-resistance mutations might become minor species in the absence of
selective drug pressure; available assays might not detect minor drug-
resistant species
Plasma viral load <1,000 HIV ribonucleic acid copies/mL Resistance assays cannot be reliably performed because of low copy
number of HIV ribonucleic acid
TABLE 4. Risks and benefits of delayed versus early therapy
initiation for the asymptomatic human immunodeficiency
virus (HIV)-infected patient*
Benefits of delayed therapy initiation
• Avoid negative effects on quality of life (i.e., inconvenience).
• Avoid drug-related adverse events.
• Delay in experiencing drug resistance.
• Preserve maximum number of available and future drug options when
HIV disease risk is highest.
Risks of delayed therapy initiation
• Possible risk for irreversible immune system depletion.
• Possible increased difficulty in suppressing viral replication.
• Possible increased risk for HIV transmission.
Benefits of early therapy initiation
• Control of viral replication easier to achieve and maintain.
• Delay or prevention of immune system compromise.
• Lower risk for resistance with complete viral suppression.
• Possible decreased risk for HIV transmission.†
Risks of early therapy initiation
• Drug-related reduction in quality of life.
• Greater cumulative drug-related adverse events.
• Earlier development of drug resistance, if viral suppression is
suboptimal.
• Limitation of future antiretroviral treatment options.
* See Table 6 for recommendations regarding when to initiate therapy.
†
The risk for viral transmission still exists; antiretroviral therapy cannot
substitute for primary HIV prevention measures (e.g., use of condoms
and safer sex practices).
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TABLE 5. Risk for progression to acquired immunodeficiency syndrome (AIDS)-defining illness among a cohort of men who
have sex with men, predicted by baseline CD4+ T cell count and viral load*
CD4 <200
Plasma viral load (copies/mL)† Percentage of AIDS-defining illness§
Reverse transcriptase-
b-deoxyribonucleic acid polymerase chain reaction n 3 years 6 years 9 years
<500 <1,500 0¶ — — —
501–3,000 1,501–7,000 3¶ — — —
3,001–10,000 7,001–20,000 7 14.3 28.6 64.3
10,001–30,000 20,001–55,000 20 50.0 75.0 90.0
>30,000 >55,000 70 85.5 97.9 100.0
CD4 201–350**
Plasma viral load (copies/mL)† Percentage of AIDS-defining illness§
Reverse transcriptase-
b-deoxyribonucleic acid polymerase chain reaction n 3 years 6 years 9 years
<500 <1,500 3¶ — — —
501–3,000 1,501–7,000 27 0 20.0 32.2
3,001–10,000 7,001–20,000 44 6.9 44.4 66.2
10,001–30,000 20,001–55,000 53 36.4 72.2 84.5
>30,000 >55,000 104 64.4 89.3 92.9
CD4 >350
Plasma Viral Load (copies/mL)† Percentage of AIDS-defining illness§
Reverse transcriptase-
b-deoxyribonucleic acid polymerase chain reaction n 3 years 6 years 9 years
<500 <1,500 119 1.7 5.5 12.7
501–3,000 1,501–7,000 227 2.2 16.4 30.0
3,001–10,000 7,001–20,000 342 6.8 30.1 53.5
10,001–30,000 20,001–55,000 323 14.8 51.2 73.5
>30,000 >55,000 262 39.6 71.8 85.0
* Adapted for this report from data from the Multicenter AIDS Cohort Study (MACS) (Source: Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA,
Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167–70. Erratum: Science 1997;275:14; adapted
by Alvaro Muñoz, Ph.D., Johns Hopkins University, Baltimore, Maryland, 2001).
† MACS numbers reflect plasma HIV ribonucleic acid (RNA) values obtained by version 2.0 b-deoxyribonucleic acid (bDNA) testing. Reverse transcriptase-
polymerase chain reaction (RT-PCR) values are consistently 2–2.5-fold higher than first-generation bDNA values, as indicated. The version 3.0 bDNA
assay provides similar HIV-1 RNA values as RT-PCR, except at the lower end of the linear range (<1,500 copies/mL). The Organon Teknika NucliSens®
HIV-1 QT assay, an in vitro nucleic acid amplification test for HIV RNA, has been approved by the Food and Drug Administration for monitoring the effects
of antiretroviral therapy among adults with baseline HIV RNA of >28,000 copies/mL.
§ In the reference study, AIDS was defined according to the 1987 CDC definition, which did not include asymptomatic persons with CD4+ T cell counts
<200 mm3.
¶ Too few subjects were in this category to provide a reliable estimate of AIDS risk.
** A recent evaluation of data from the MACS cohort of 231 persons with CD4+ T cell counts >200 and <350 cells/mm3 demonstrated that of 40 (17%)
persons with plasma HIV RNA <10,000 copies/mL, none had progressed to AIDS by 3 years (personal communication, Alvaro Muñoz, Johns Hopkins
University, Baltimore, Maryland, 2001). Of 28 persons (29%) with plasma viremia of 10,000–20,000 copies/mL, 4% and 11% had progressed to AIDS at 2
and 3 years, respectively. Plasma HIV RNA was calculated as RT-PCR values from measured bDNA values.
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TABLE 6. Indications for initiating antiretroviral therapy for the chronically human immunodeficiency virus (HIV)-1–infected
patient
The optimal time to initiate therapy is unknown among persons with asymptomatic disease and CD4+ T cell counts of >200 cells/mm3. This table provides
general guidance rather than absolute recommendations for an individual patient. All decisions regarding initiating therapy should be made on the basis of
prognosis as determined by the CD4+ T cell count and level of plasma HIV RNA indicated in this table, the potential benefits and risks of therapy indicated
in Table 4, and the willingness of the patient to accept therapy.
Plasma HIV ribonucleic
Clinical category CD4+ cell count acid (RNA) Recommendation
* Clinical benefit has been demonstrated in controlled trials only for patients with CD4
+
 T cells <200/mm
3
; however, the majority of clinicians would offer
therapy at a CD4
+
 T cell threshold of <350/mm
3
. A recent evaluation of data from the Multicenter AIDS Cohort Study (MACS) of 231 persons with CD4
+
 T
cell counts >200 and <350 cells/mm
3
 demonstrated that of 40 (17%) persons with plasma HIV RNA <10,000 copies/mL, none progressed to AIDS by 3
years (personal communication, Alvaro Muñoz, Johns Hopkins University, Baltimore, Maryland, 2001). Of 28 persons (29%) with plasma viremia of
10,000–20,000 copies/mL, 4% and 11% progressed to AIDS at 2 and 3 years, respectively. Plasma HIV RNA was calculated as RT-PCR values from
measured bDNA values (for additional information, see Considerations for Initiating Therapy for the Patient with Asymptomatic HIV Infection).
†
Although a 2–2.5-fold difference existed between RT-PCR and the first bDNA assay (version 2.0), with the 3.0 version bDNA assay, values obtained by










CD4+ T cells <200/mm3
CD4+ T cells >200/mm3
but <350/mm3
CD4+ T cells >350/mm3






chain reaction [RT-PCR] or
b-deoxyribonucleic acid
[bDNA])†




Treatment should be offered, although controversial*
Certain experienced clinicians recommend initiating therapy,
recognizing that the 3-year risk for untreated patients to experience
AIDS is >30%; in the absence of increased levels of plasma HIV
ribonucleic acid (RNA), other clinicians recommend deferring
therapy and monitoring the CD4+ T cell count and level of plasma
HIV RNA more frequently; clinical outcome data after initiating
therapy are lacking
Certain experienced clinicians recommend deferring therapy and
monitoring the CD4+ T cell count, recognizing that the 3-year risk
for untreated patients to experience AIDS is <15%
TABLE 7. Strategies to improve adherence—patient and
medication-related
• Inform patient regarding side effects.
• Anticipate and treat side effects.
• Simplify food requirements.
• Avoid adverse drug interactions.
• If possible, reduce dose frequency and number of pills.
• Negotiate a treatment plan that the patient understands and to which
he or she commits.
• Spend time and multiple encounters to educate and explain goals of
therapy and need for adherence.
• Establish readiness to take medication before writing first prescription.
• Recruit family and friends to support the treatment plan.
• Develop concrete plan for specific regimen by considering meal
schedule, daily routines, and side effects.
• Provide written schedule and pictures of medications, daily or weekly
pill boxes, alarm clocks, pagers, or other mechanical aids for
adherence.
• Develop adherence support groups or add adherence concerns to
agenda of other support groups.
• Develop links with local community-based organizations regarding
adherence combined with educational sessions and practical
strategies.
• Consider practice sessions using candy instead of pills.
TABLE 8. Strategies to improve adherence—clinician and
health team-related
• Establish trust.
• Serve as educator and information source with ongoing support and
monitoring.
• Provide access between visits for questions or problems (e.g., by
providing a pager number), including during vacations or conferences.
• Monitor ongoing adherence; intensify management during periods of
suboptimal adherence (i.e., more frequent visits, recruitment of family
or friends, deployment of other team members, and referral for mental
health or chemical-dependency services).
• Use health team for all patients, including patients with special needs
(e.g., use peer educators for adolescents or for injection-drug users).
• Consider impact of new diagnoses on adherence (e.g., depression,
liver disease, wasting, or recurrent chemical dependency) and include
adherence intervention in management.
• Use nurses, pharmacists, peer educators, volunteers, case managers,
drug counselors, clinician's assistants, nurse practitioners, and
research nurses to reinforce adherence messages.
• Provide training to support team regarding antiretroviral therapy and
adherence.
• Add adherence interventions to job descriptions of support team
members; add continuity-of-care role to improve patient access.
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TABLE 9. Interventions to improve adherence
• Pharmacist-based adherence encounters and clinics.
• Multidisciplinary adherence encounters at each visit.
• Reminders, alarms, pagers, or timers on pillboxes.
• Patient education aids, including regimen pictures, calendars, or
stickers.
• Clinician education aids (e.g., medication guides, pictures, or
calendars).
TABLE 10. Goals of human immunodeficiency virus (HIV)
therapy and tools to achieve them
Goals
• Maximal and durable suppression of viral load.
• Restoration or preservation of immunologic function.
• Improvement in quality of life.
• Reduction of HIV-related morbidity and mortality.
Tools
• Maximum adherence to the antiretroviral regimen.
• Rational sequencing of drugs.
• Preservation of future treatment options.













• Clinical, virologic, and
immunologic efficacy well-
documented




• Targets HIV at two steps of
viral replication (reverse
transcriptase and PI)
• Spares PI-related side
effects
• Easier to use and adhere
to, compared with PIs
• Usually easier to use and
adhere to, compared with
PIs
• Spares PI and NNRTI side
effects
• Resistance to one NRTI
does not confer cross-
resistance throughout class
• Might be difficult to use
and adhere to









by a single or limited
number of mutations









• Mild to severe inhibition
of cytochrome P450
pathway; ritonavir is most
potent inhibitor, but this
effect can be exploited to
boost levels of other PIs
• Fewer drug interactions
compared with PIs
• Usually manageable drug
interaction problems
• Preserves NNRTIs for
use in treatment failure
• Resistance primes for
cross-resistance with
other PIs
• Preserves PIs for later
use




• Preserves both PI and
NNRTI classes for later
use
• Limited cross-resistance
within the NRTI class
TABLE 11. Advantages and disadvantages of class-sparing regimens used in human immunodeficiency virus (HIV) therapy
Drug-interaction Impact on
Regimen Possible advantages Possible disadvantages complications future options
* Certain side effects being attributed to PI therapy (e.g., lipodystrophy) have not been reported to be associated strictly with using PI-containing regimens.
Lipodystrophy has also been described among patients on NRTIs alone and among patients not on antiretroviral therapy.
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TABLE 12. Recommended antiretroviral agents for initial treatment of established human immunodeficiency virus (HIV) infection
This table is a guide to using available treatment regimens for patients with no previous or limited experience with HIV therapy. In accordance with
established therapy goals, priority is assigned to regimens in which clinical trial data demonstrate 1) sustained suppression of HIV plasma ribonucleic acid
(including among patients with high baseline viral load); 2) sustained increase in CD4+ T cell count (for the majority of patients, during 48 weeks); and 3)
favorable clinical outcome (i.e., delayed progression to acquired immunodeficiency syndrome and death). Regimens that have been compared directly with
other regimens that perform sufficiently well with regard to these parameters are included in the strongly recommended category. Other factors considered
included the regimen’s pill burden, dosing frequency, food requirements, convenience, toxicity, and drug-interaction profile compared with other regimens.
All antiretroviral agents, including those in the strongly recommended category, have potentially serious toxic and adverse events associated with their use.
Clinicians should consult Tables 13–20 before formulating an antiretroviral regimen for their patients. Antiretroviral drug regimens include one choice each
from columns A and B of this table. Drugs are listed in alphabetical, not priority order.
Recommendation Column A Column B
Strongly Recommended Efavirenz Didanosine plus lamivudine
Indinavir Stavudine plus didanosine**
Nelfinavir Stavudine plus lamivudine
Ritonavir plus indinavir*† Zidovudine plus didanosine
Ritonavir plus lopinavir*§ Zidovudine plus lamivudine
Ritonavir plus saquinavir* (soft-gel capsule¶ or hard-gel capsule¶)
Recommended as alternatives Abacavir Zidovudine plus zalcitabine
Amprenavir
Delavirdine








Not recommended and should not be offered Saquinavir (hard-gel capsule)*** Stavudine plus zidovudine
(All monotherapies whether from column A or B¶¶) Zalcitabine plus didanosine
Zalcitabine plus lamivudine
Zalcitabine plus stavudine
* See text for additional information regarding optimizing protease inhibitor exposure with ritonavir.
† Recommendation is based on the opinions of specialists in HIV treatment.
§ Coformulated as Kaletra™ (Abbott Laboratories).
¶ Saquinavir (soft-gel capsule) refers to Fortovase® (Roche Laboratories, Inc.); Saquinavir (hard-gel capsule) refers to Invirase® (Roche Laboratories, Inc.).
** Pregnant women might be at increased risk for lactic acidosis and liver damage when treated with stavudine plus didanosine. This combination should be
used for pregnant women only when the potential benefit outweighs the potential risk.
†† This category includes drugs or combinations for which information is too limited to allow a recommendation for or against use.
§§ Data from clinical trials are limited to use in salvage. Data from trials of tenofovir as initial therapy should be available in the future.
¶¶ Zidovudine monotherapy can be considered for prophylactic use among pregnant women with low viral load and high CD4+ T cell counts to prevent
perinatal transmission (see Considerations for Antiretroviral Therapy Among HIV-Infected Pregnant Women).
*** Use of saquinavir (hard-gel capsule) (i.e., Invirase) is only recommended in combination with ritonavir.
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TABLE 13. Characteristics of nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs)
Generic name/ Dosing Oral Serum Intracellular
trade name Form recommendations Food effect bioavailability half-life half-life Elimination Adverse events
* Each Combivir tablet contains 300 mg zidovudine and 150 mg lamivudine.
† Each Trizivir tablet contains 300 mg zidovudine, 150 mg lamivudine, and 300 mg abacavir.
§ For once-daily dosing only. Twice-daily dosing is preferred; however, once-daily dosing might be appropriate for patients who require a simplified dosing schedule.
¶ Twice-daily dosing is preferred; however, once-daily dosing might be appropriate for patients who require a simplified dosing schedule.
** Cases of fatal and nonfatal pancreatitis have occurred among treatment-naïve and treatment-experienced patients during therapy with didanosine alone or in combination with
other drugs, including stavudine or stavudine plus hydroxyurea.
†† Pregnant women might be at increased risk for lactic acidosis and liver damage when treated with the combination of stavudine and didanosine. This combination should be used
for pregnant women only when the potential benefit outweighs the potential risk.
§§ Rare and sometimes fatal cases of ascending neuromuscular weakness resembling Guillain-Barré syndrome in association with hyperlactatemia have been reported when
stavudine is part of an NRTI combination.
¶¶ Patients who experience signs or symptoms of hypersensitivity, which include fever, rash, fatigue, nausea, vomiting, diarrhea, and abdominal pain, should discontinue abacavir as
soon as a hypersensitivity reaction is suspected. Abacavir should not be restarted because more severe symptoms will recur within hours and can include life-threatening
hypotension and death. Cases of abacavir hypersensitivity syndrome should be reported to the Abacavir Hypersensitivity Registry (800-270-0425).
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(glucuronidated metabolites;
<5% unchanged); 10% in
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P450 (3A inhibitor); 51%
excreted in urine (<5%
unchanged); 44% in feces
Metabolized by cytochrome



















TABLE 14. Characteristics of nonnucleoside reverse transcriptase inhibitors (NNRTIs)
Generic name/ Dosing Oral Serum
trade name Form recommendations Food effect bioavailability half-life Elimination Adverse events
Note: For information regarding drug interactions, see Tables 17–19.
* During clinical trials, NNRTI was discontinued because of rash among 7% of patients taking nevirapine, 4.3% of patients taking delavirdine, and 1.7% of patients taking efavirenz.




Adverse events can include dizziness, somnolence, insomnia, abnormal dreams, confusion, abnormal thinking, impaired concentration, amnesia, agitation, depersonalization,
hallucinations, and euphoria. Overall frequency of any of these symptoms associated with use of efavirenz was 52%, as compared with 26% among control subjects; 2.6% of those
persons on efavirenz discontinued the drug because of these symptoms. Symptoms usually subside spontaneously after 2–4 weeks.
¶
Data are unavailable regarding teratogenicity of other NNRTIs among nonhuman primates.
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TABLE 15. Characteristics of protease inhibitors (PIs)
Generic name/ Dosing Oral Serum Route of
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TABLE 15. (Continued) Characteristics of protease inhibitors (PIs)
Generic name/ Dosing Oral Serum Route of
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children aged <4 years,
patients with hepatic or renal
failure, and patients treated












Note: For information regarding drug interactions, see Tables 17–19.
* Cases of worsening glycemic control among patients with preexisting diabetes, and cases of new-onset diabetes, including diabetic ketoacidosis, have been reported with the use
of all PIs.
†
Fat redistribution and lipid abnormalities have been recognized increasingly with the use of PIs. Patients with hypertriglyceridemia or hypercholesterolemia should be evaluated for
risk for cardiovascular events and pancreatitis. Interventions can include dietary modification, lipid-lowering agents, or discontinuation of PIs.
§
Dose escalation for ritonavir—days 1 and 2: 300 mg two times/day; days 3–5: 400 mg two times/day; days 6–13: 500 mg two times/day; day 14: 600 mg two times/day. Combination
treatment regimen with saquinavir is 400 mg by mouth two times/day, plus ritonavir 400 mg by mouth two times/day.
¶
Saquinavir soft-gel capsule administered as 1,600 mg two times/day produced lower daily exposure and trough serum concentrations compared with the standard 1,200 mg three
times/day regimen. Trends in immunologic and virologic responses favored the standard three times/day regimen. Clinical significance of the inferior trends observed in the two
times/day dosing group are unknown; however, until results are available from longer follow-up studies, two times/day dosing of saquinavir soft-gel capsules is not recommended.
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TABLE 16. Food and Drug Administration box warnings in product labeling for antiretroviral agents
The Food and Drug Administration can require that warnings regarding special problems associated with a prescription drug, including those that might lead to death or serious
injury, be placed in a prominently displayed box, commonly known as a black box. Please note that other serious toxicities associated with antiretroviral agents are not listed in this
table (see Tables 13–15, 17–20 for more extensive lists of adverse effects associated with antiretroviral drugs or for drug interactions).
Antiretroviral drug Pertinent box warning information




























• Fatal hypersensitivity reactions reported
— Signs or symptoms include fever, skin rash, fatigue, gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, or abdominal pain),
and respiratory symptoms (e.g., pharyngitis, dyspnea, or cough)
— Abacavir should be discontinued as soon as hypersensitivity reaction is suspected
— Abacavir should not be restarted
— If restarted, more severe symptoms will recur within hours and might include life-threatening hypotension and death
• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside
analogues alone or in combination
• Because of potential risk for toxicity from substantial amounts of the excipient propylene glycol in Agenerase oral solution, it is contraindi-
cated for the following patient populations:
— children aged <4 years
— pregnant women
— patients with renal or hepatic failure
— patients treated with disulfiram or metronidazole
• Oral solution should be used only when Agenerase capsules or other protease inhibitors cannot be used
No box warning; for a list of adverse events associated with delavirdine, see Table 14
• Fatal and nonfatal pancreatitis have occurred with didanosine alone or in combination with other antiretroviral agents
— Didanosine should be withheld if pancreatitis is suspected
— Didanosine should be discontinued if pancreatitis is confirmed
• Fatal lactic acidosis has been reported among pregnant women who received a combination of didanosine and stavudine with other
antiretroviral combinations
— Didanosine and stavudine combination should only be used during pregnancy if the potential benefit clearly outweighs the potential risks
• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside
analogues alone or in combination
No box warning; for a list of adverse events associated with efavirenz, see Table 14
No box warning; for a list of adverse events associated with indinavir, see Table 15
• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside
analogues alone or in combination
No  box warning; for a list of adverse events associated with lopinavir/ritonavir, see Table 17
No box warning; for a list of adverse events associated with nelfinavir, see Table 17
• Severe, life-threatening hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis, and hepatic failure; patients should be
advised to seek medical evaluation immediately if signs and symptoms of hepatitis occur
• Severe, life-threatening, and even fatal skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitiv-
ity reactions characterized by rash, constitutional findings, and organ dysfunction have occurred with nevirapine treatment
• Patients should be monitored intensively during the first 12 weeks of nevirapine therapy to detect potentially life-threatening hepatotoxicity
or skin reactions
• A 14-day lead-in period with nevirapine 200-mg daily must be followed strictly
• Nevirapine should not be restarted after severe hepatic, skin, or hypersensitivity reactions
• Coadministration of ritonavir with certain medications can result in potentially serious or life-threatening adverse events because of effects
of ritonavir on hepatic metabolism of certain drugs
No box warning; for a list of adverse events associated with saquinavir, see Table 17
• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside
analogues alone or in combination
• Fatal lactic acidosis has been reported among pregnant women who received combination of stavudine and didanosine with other
antiretroviral combinations
— Stavudine and didanosine combination should only be used during pregnancy if the potential benefit clearly outweighs the potential risks
• Fatal and nonfatal pancreatitis have occurred when stavudine was part of a combination regimen with didanosine with or without
hydroxyurea
• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone
or in combination with other antiretrovirals
• Zalcitabine can cause severe peripheral neuropathy; use with caution among patients with preexisting neuropathy
• In rare cases, zalcitabine can cause pancreatitis; therapy should be withheld until pancreatitis is excluded
• Rare cases of hepatic failure and death have been reported among patients with underlying hepatitis B infection
• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside
analogues alone or in combination
• Zidovudine can be associated with hematologic toxicities, including granulocytopenia and severe anemia, including among advanced HIV
patients
• Prolonged zidovudine use has been associated with symptomatic myopathy
• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside
analogues alone or in combination
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TABLE 17. Drugs that should not be used with protease inhibitor or nonnucleoside reverse transcriptase inhibitor antiretrovirals
Calcium Lipid-
Drug channel lowering Gastrointestinal Ergot alkaloids




































































































































































     —
     —
     —
* This effect probably applies to the entire class.
†
Certain listed drugs are contraindicated on the basis of theoretical considerations; thus, drugs with low therapeutic indices, but with suspected major metabolic contribution from
cytochrome P450 3A, CYP2D6, or unknown pathways, are included in this table. Actual interactions might not occur among patients.
Suggested Alternatives
Simvastatin, lovastatin: Atorvastatin, pravastatin, fluvastatin, cerivastatin (alternatives should be used with caution).
Rifabutin: Clarithromycin, azithromycin (Mycobacterium avium-intracellulare prophylaxis); clarithromycin, ethambutol (Mycobacterium avium-intracellulare treatment).
Rifampin: Rifabutin (Mycobacterium tuberculosis)
Astemizole, terfenadine: Loratadine, fexofenadine, cetirizine.
Midazolam, triazolam: Temazepam, lorazepam.
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TABLE 18. Drug interactions between antiretrovirals and other drugs, requiring dose modification or cautious use: protease
inhibitors, nonnucleoside reverse transcriptase inhibitors, and nucleoside reverse transcriptase inhibitors
Drugs Antifungals Antimycobacterials












68%; dose: indinavir 600 mg
three times/day
Ketoconazole levels increase
three times; dose: use with
caution; do not exceed 200
mg/day
Saquinavir levels increase







tion curve decreases 13%;
ketoconazole increases


















using ritonavir plus saquinavir,
then use rifampin 600 mg





decreases 82%; no change
in rifampin blood concentra-
tion curve; avoid concomitant
use
Lopinavir blood concentra-
tion curve decreases 75%;
avoid concomitant use
Nevirapine levels decrease





25%; clinical significance is
unknown
Indinavir levels decrease 32%;
rifabutin increases two times;
dose: decrease rifabutin to 150
mg daily or 300 mg 2–3 times/
week; indinavir, 1,000 mg three
times/day
Rifabutin levels increases four
times; dose: decrease rifabutin




40%; no dose adjustment
unless using ritonavir plus
saquinavir; then use rifabutin
150 mg 3 times/week
Nelfinavir levels decrease 32%;
rifabutin increases two times;
dose: decrease rifabutin to 150
mg every day or 300 mg 2–3
times/week; increase nelfinavir
dose to 1,000 mg three times/
day
Amprenavir blood concentration
curve decreases 15%; rifabutin
increases 193%; dose: no
change in amprenavir dose;
decrease rifabutin to 150 mg
every day or 300 mg 3 times/
week
Rifabutin blood concentration
curve increases 3-fold; 25-O-
desacetyl metabolite increases
47.5-fold; decrease rifabutin
dose to 150 mg every other
day; lopinavir: standard dose
Nevirapine levels decrease
16%; no dose adjustment*
Delavirdine levels decrease
80%; rifabutin increases 100%;
not recommended
Efavirenz unchanged; rifabutin
decreases 35%; dose: increase
rifabutin dose to 450–600 mg
every day or 600 mg 3 times/
week;* efavirenz: standard dose
Clarithromycin levels








increases 177%; no dose
adjustment
                      —
Amprenavir blood
concentration curve




                      —
Nevirapine levels increase
26%; clarithromycin

































                      —
Ethinyl estradiol increases
37%; data are unavailable
regarding other compo-
nents; use alternative or
additional methods
* Data are unavailable.
†
Drugs for which plasma concentrations might be decreased by coadministration with ritonavir include anticoagulants (warfarin), anticonvulsants (phenytoin, divaproex, lamotrigine),
and antiparasitics (atovaquone).
§
Drug-interaction studies were conducted with Invirase;
®
 therefore, recommendations might not apply to use with Fortovase.
®
Drugs Antifungals Antimycobacterials
affected Ketoconazole Rifampin Rifabutin Clarithromycin Oral contraceptives
Nonnucleoside reverse transcriptase inhibitors
* These recommendations apply to regimens that do not include protease inhibitors, which can substantially increase rifabutin levels.
†
Data are unavailable.
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Potential for substantial
increase in statin levels;
avoid concomitant use
Potential for substantial
increase in statin levels;
avoid concomitant use
Potential for substantial









indinavir blood concentration curve;
consider alternative agent
Carbamazepine toxicity has been reported
after introduction of ritonavir; use with
caution; monitor anticonvulsant levels
closely
Unknown, but might decrease saquinavir
levels substantially; monitor anticonvulsant
levels
Unknown, but might decrease nelfinavir
levels substantially; monitor anticonvulsant
levels
Unknown, but might decrease amprenavir
levels substantially; monitor anticonvulsant
levels
Unknown, but might decrease lopinavir
levels substantially; monitor anticonvulsant
levels




                      —
Nelfinavir might decrease
methadone levels, but has
minimal effect on
maintenance dose; monitor




decrease by 35%; monitor
and titrate dose, if needed;





and titrate dose if needed;
might require increased
methadone dose
Grapefruit juice decreases indinavir levels
by 26%; sildenafil blood concentration
curve increases by 340%; do not exceed
25 mg in a 48-hour period
Desipramine increases 145%; reduce
dose; theophylline decreases 47%;
monitor theophylline levels; multiple
possible interactions; sildenafil blood
concentration levels increase 2-fold. Do
not exceed 25 mg in a 48-hour period
Grapefruit juice increases saquinavir
levels; dexamethasone decreases
saquinavir levels; sildenafil blood
concentration curve increases 2–11-fold;
use a 25-mg starting dose of sildenafil
Sildenafil blood concentration curve
expected to increase; do not exceed 25
mg in a 48-hr period
Sildenafil blood concentration curve
expected to increase; do not exceed 25
mg in a 48-hr period
Probable substantial increase in sildenafil
blood concentration curve; do not exceed
25 mg in a 48-hr period
Potential for substantial increase in statin levels;
avoid concomitant use. Simvastatin blood concentra-
tion increases 505%; not recommended. Potential for
substantial increase in lovastatin blood concentration;
not recommended. Atorvastatin blood concentration
levels increase 74%; use with caution
Potential for substantial increase in statin levels;
avoid concomitant use with lovastatin and simvastatin
Potential for substantial increase in statin levels;
avoid concomitant use; atorvastatin blood concentra-
tion curve increases 5.88-fold; use with caution and
monitoring; pravastatin blood concentration curve
increases 33%; no dosage adjustment necessary
                               —†
Potential for substantial increase
in statin levels; avoid concomitant use
                               —
TABLE 18. (Continued) Drug interactions between antiretrovirals and other drugs, requiring dose modification or cautious use:
protease inhibitors, nonnucleoside reverse transcriptase inhibitors, and nucleoside reverse transcriptase inhibitors
Lipid-lowering agents Anticonvulsants
Simvastatin Lovastatin Atorvastatin Pravastatin Phenobarbitol Phenytoin Carbamazepine Methadone Miscellaneous
Protease inhibitors (Continued)
Lipid-lowering agents Anticonvulsants
Simvastatin Lovastatin Phenobarbitol Phenytoin Carbamazepine Methadone Miscellaneous
Nonnucleoside reverse transcriptase inhibitors (Continued)
Unknown; use with caution; monitor anticonvulsant levels
Unknown, but might decrease delavirdine levels
substantially; monitor anticonvulsant levels




titrate methadone dose to
effect
                      —
Methadone levels
decrease by 52%; titrate
methadone dose to effect
                             —
Might increase levels of dapsone, warfarin,
and quinidine; sildenafil: potential for
increased concentrations and adverse
effects; do not exceed 25 mg in a 48-hour
period
Monitor warfarin when used concomitantly
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TABLE 18. (Continued) Drug interactions between antiretrovirals and other drugs, requiring dose modification or cautious use:
protease inhibitors, nonnucleoside reverse transcriptase inhibitors, and nucleoside reverse transcriptase inhibitors
Drugs affected Methadone Cidofovir, ganciclovir, or valganciclovir Miscellaneous






Stavudine levels decrease 27%; methadone is
unchanged; no dose adjustment
Didanosine levels decrease 41%; methadone






Possibly competes for active tubular secretion;
might increase serum concentration of
cidofovir, ganciclovir, valganciclovir, or
tenofovir; monitor for dose-related toxicities
Ribavirin inhibits phosphorylation of zidovudine




Didanosine levels increase 44%; peak plasma
concentration increases by 28%
* Data are unavailable.
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TABLE 19. Drug effects on blood concentration curves per dose: protease inhibitors and nonnucleoside reverse transcriptase
inhibitors







Indinavir levels increase 2–5
times; dose: indinavir 400 mg two
times/day plus ritonavir 400 mg
two times/day; or indinavir 800
mg two times/day plus ritonavir
100 or 200 mg two times/day
                      —§
                      —
                      —









400 mg two times/day
plus ritonavir 400 mg
two times/day
                —
                —
                —
Indinavir levels increase 50%;
nelfinavir levels increase 80%;
dose: limited data for indinavir;
1,200 mg two times/day plus
nelfinavir 1,250 mg two times/
day
Ritonavir, no effect; nelfinavir
increases 1.5 times; dose:
ritonavir 400 mg two times/day




20%;† dose: standard nelfinavir;
Fortovase® 800 mg three times/
day or 1,200 mg two times/day
                       —
                       —
Amprenavir blood concen-
tration curve increases
 33%; dose: no change
Amprenavir blood concen-
tration curve increases
2.5-fold; Food and Drug
Administration-approved
dosing: amprenavir 600 mg two
times/day plus ritonavir 100 mg
two times/day or amprenavir
1,200 mg one time/day plus
ritonavir 200 mg one time/day
Amprenavir blood concen-
tration curve decreases
32%; dose: insufficient data
Amprenavir blood concen-
tration curve increases
1.5-fold; dose: insufficient data
                    —
Indinavir blood concentra-
tion curve and minimum
concentration increase;









800 mg two times/day;
lopinavir, standard dose





600–750 mg two times/day;
lopinavir, standard dose
* Drug interaction studies have been completed with saquinavir administered as Invirase® or Fortovase.® Results from studies conducted with Invirase might not be applicable to Fortovase.
†




Study conducted with Invirase.
Drug affected Nevirapine Delavirdine Efavirenz










Indinavir decreases 28%; nevirapine, no
effect; dose: indinavir 1,000 mg every 8
hours; nevirapine, standard dose
Ritonavir decreases 11%; nevirapine, no
effect; standard dose
Saquinavir decreases 25%; nevirapine,
no effect; dose: data unavailable
Nelfinavir increases 10%; nevirapine, no
effect; standard dose
Potential decreases in amprenavir level†
Lopinavir minimum concentration
decreases 55%; dose: consider lopinavir





Indinavir increases >40%; delavirdine, no effect;
dose: indinavir 600 mg every 8 hours; delavirdine,
standard dose
Ritonavir increases 70%; delavirdine, no effect;
dose: delavirdine, standard dose; ritonavir, data
unavailable
Saquinavir increases 5 times;* delavirdine, no effect;
dose: Fortovase® 800 mg three times/day; delavirdine,
standard but monitor transaminase levels
Nelfinavir increases 2 times; delavirdine
decreases 50%; dose: data unavailable but
monitor for neutropenic complications
—




Indinavir decreases 31%; dose: indinavir 1,000 mg every 8
hours; efavirenz, standard dose
Ritonavir increases 18%; efavirenz increases 21%; dose:
ritonavir 600 mg two times/day (500 mg two times/day for
intolerance); efavirenz, standard dose
Saquinavir decreases 62%;* efavirenz decreases 12%;
coadministration not recommended when saquinavir is used
as a single PI
Nelfinavir increases 20%; standard dose
Amprenavir blood concentration curve decreases 36%; dose:
amprenavir 1,200 mg three times/day as single protease
inhibitor or 1,200 mg two times/day plus ritonavir 200 mg two
times/day; efavirenz, standard dose
Lopinavir blood concentration curve decreases 40%;
efavirenz, no change; dose: consider lopinavir 533/133 mg
two times/day for protease inhibitor-experienced patients;
efavirenz, standard dose
Nevirapine, no effect; efavirenz blood concentration curve
decreases 22 %
—
* Study conducted with Invirase.®
†
Data are unavailable.
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TABLE 21. Guidelines for changing an antiretroviral regimen because of suspected drug failure
• Criteria for changing therapy include 1) a suboptimal reduction in plasma viremia after initiation of therapy, 2) reappearance of viremia after suppres-
sion to undetectable levels, 3) substantial increases in plasma viremia from the nadir of suppression, and 4) declining CD4+ T cell numbers.
• Before deciding to change therapy on the basis of viral load, a second test should be used to confirm viral load determination.
• Clinicians should distinguish between the need to change a regimen because of drug intolerance or inability to comply with the regimen versus failure
to achieve sustained viral suppression; single agents can be changed for patients with drug intolerance.
• A single drug should not be changed or added to a failing regimen; using >2 new drugs or using a new regimen with >3 new drugs is preferable. If
susceptibility testing indicates resistance to one agent only in a combination regimen, replacing only that drug is possible; however, this approach
requires clinical validation.
• Certain patients have limited options for new regimens of desired potency; in selected cases, continuing the previous regimen if partial viral suppres-
sion was achieved is a rational option.
• In certain situations, regimens identified as suboptimal for initial therapy because of limitations imposed by toxicity, intolerance, or nonadherence, are
rational options, including in late-stage disease. For patients with no rational options who have virologic failure with return of viral load to baseline (i.e.,
pretreatment levels) and declining CD4+ T cell counts, discontinuing antiretroviral therapy should be considered.
• Experience is limited regarding regimens that use combinations of two protease inhibitors or combinations of protease inhibitors with nonnucleoside
reverse transcriptase inhibitors; for patients with limited options because of drug intolerance or suspected resistance, these regimens provide
alternative options.
• Information is limited regarding the value of restarting a drug that the patient has previously received. Susceptibility testing might be useful if clinical
evidence indicating emergence of resistance is observed. However, testing for phenotypic or genotypic resistance in peripheral blood virus might fail
to detect minor resistant variants. Thus, the presence of resistance is more useful information in altering treatment strategies than the absence of
detectable resistance.
• Clinicians should avoid changing from ritonavir to indinavir or vice versa for drug failure because high-level cross-resistance is probable.
• Clinicians should avoid changing among nonnucleoside reverse transcriptase inhibitors for drug failure because high-level cross-resistance is
probable.
• Decisions to change therapy and choices of new regimens requires the clinician to have substantial experience and knowledge regarding the care of
persons living with human immunodeficiency virus infection. Clinicians who are less experienced are strongly encouraged to obtain assistance










































































TABLE 20. Human immunodeficiency virus-related drugs with overlapping toxicities
Bone marrow Peripheral Ocular
suppression neuropathy Pancreatitis Nephrotoxicity Hepatotoxicity Rash Diarrhea effects
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TABLE 22. Associated signs and symptoms of acute retroviral





— Erythematous maculopapular with lesions on face, trunk, or
extremities, including palms and soles
— Mucocutaneous ulceration involving mouth, esophagus, or genitals
• Myalgia or arthralgia 54%
• Diarrhea 32%
• Headache 32%
• Nausea and vomiting 27%
• Hepatosplenomegaly 14%
• Weight loss 13%
• Thrush 12%
• Neurologic symptoms 12%
— Meningoencephalitis or aseptic meningitis




— Cognitive impairment or psychosis
Source: Niu MT, Stein DS, Schnittman SM. Primary human
immunodeficiency virus type 1 infection: review of pathogenesis and early
treatment intervention in humans and animal retrovirus infections. J Infect
Dis 1993;168:1490–501.
TABLE 23. Zidovudine perinatal transmission prophylaxis
regimen
Antepartum Initiation at 14–34 weeks gestation and continued
throughout pregnancy of either Regimen A or B, as
follows:
Regimen A. Pediatric AIDS Clinical Trials Group
protocol 076 regimen: zidovudine 100 mg five times/day.
Regimen B. Acceptable alternative regimen: zidovudine
200 mg three times/day or zidovudine 300 mg two
times/day.
Intrapartum During labor, zidovudine 2 mg/kg of mother's body
weight, intravenously for 1 hour, followed by a continu-
ous infusion of 1 mg/kg of mother's body weight,
intravenously until delivery.
Postpartum Oral administration of zidovudine to the newborn infant
(zidovudine syrup, 2 mg/kg of infant's body weight every
6 hours) for the first 6 weeks of life, beginning at 8–12
hours after birth.
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TABLE 24. Preclinical and clinical data concerning using antiretrovirals during pregnancy
Food and Drug
Antiretroviral Administration Placental passage Long-term animal

































Positive, near lethal dose
Positive, hydrocephalus at high dose
Negative
Negative, but sternal bone calcium
decreases
Negative
Positive, anasarca and skeletal
malformations at 1,000 mg/kg body




administered to juvenile animals at
higher doses
Negative, but extra ribs among rats
Negative, but cryptorchidism among
rats§
Negative
Positive, thymic elongation; incomplete
ossification of bones; low body weight
Negative, but delayed skeletal
ossification and increase in skeletal
variations among rats at maternally
toxic doses
Negative




* Food and Drug Administration pregnancy categories:
A Adequate and well-controlled studies of pregnant women fail to demonstrate a risk to the fetus during the first trimester of pregnancy (and no evidence exists of risk during later
trimesters.
B Animal reproduction studies fail to demonstrate a risk to the fetus, and adequate but well-controlled studies of pregnant women have not been conducted.
C Safety in human pregnancy has not been determined; animal studies are either positive for fetal risk or have not been conducted, and the drug should not be used unless the
potential benefit outweighs the potential risk to the fetus.
D Positive evidence of human fetal risk that is based on adverse reaction data from investigational or marketing experiences, but the potential benefits from the use of the drug
among pregnant women might be acceptable despite its potential risks.
X Studies among animals or reports of adverse reactions have indicated that the risk associated with the use of the drug for pregnant women clearly outweighs any possible
benefit.
†
Despite certain animal data indicating potential teratogenicity of zidovudine when near-lethal doses are given to pregnant rodents, substantial human data are available indicating
that the risk to the fetus, if any, is limited when administered to the pregnant mother beyond 14 weeks gestation. Follow-up for <6 years for 734 infants who had been born to HIV-
infected women and had had in utero exposure to zidovudine has not documented any tumor development (Source: Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of
human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999;179:871–82). However, no data are available regarding longer follow-up
for late effects.
§
These effects occurred only at maternally toxic doses.
Positive; rodent, vaginal tumors
Positive; rodent, thymic lymphomas
Negative; no tumors, lifetime rodent
study
Positive; rodent, liver and bladder
tumors






Positive; rodent, liver tumors
Incomplete
Incomplete
Lopinavir: incomplete; ritonavir: see
previous row
Incomplete




Yes, rhesus macaques (0.30–0.50)
Yes, human (0.5)




Yes, rats and cynomolgus monkeys
Yes, rats (substantial among rats; low
among rabbits)




Lopinavir: yes, rats (0.08 at 6 hours
after dose)
Yes, human (~1.0)
Yes, rats (late-term fetus, blood, 0.15;
late-term fetus, liver 0.04)
Yes, cynomolgus monkeys, rats,
rabbits (~1.0)
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List of Abbreviations Used
in This Report
AIDS acquired immunodeficiency syndrome
ATIS HIV/AIDS Treatment Information Service
bDNA b-deoxyribonucleic acid
BMD bone mineral density
Cmax peak plasma concentration
CYP450 cytochrome P450
CT computed tomography
DEXA dual energy radiograph absorptiometry
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOT directly observed therapy
DRESS drug rash with eosinophilia and systemic
symptoms
FDA Food and Drug Administration
HAART highly active antiretroviral therapy
HELLP hemolysis, elevated liver enzymes and low
platelets






MACS Multicenter AIDS Cohort Study
MSM men who have sex with men
MEMS medication event monitoring system
MRI magnetic resonance imaging
N-9 nonoxynol-9
NIH National Institutes of Health
NNRTI nonnucleoside reverse transcriptase inhibitor
NPIN National Prevention Information Network
NRTI nucleoside reverse transcriptase inhibitor
OI opportunistic infection





RT-PCR reverse transcriptase-polymerase chain reaction
SJS Stevens-Johnson syndrome
STI structured or supervised treatment interruptions
TEN toxic epidermal necrosis
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1. All chronically HIV-infected, asymptomatic persons with <350 CD4+




2. Pregnant women should not receive full combination therapy because




3. Data clearly support a recommendation that all HIV-infected persons




4. No chronically HIV-infected, asymptomatic person with a CD4+ T cell




5. Zidovudine can be administered in combination with stavudine.
A. True.
B. False.
6. When initiating antiretroviral therapy, strongly recommended
regimens include . . .
A. two nucleoside-analogue reverse transcriptase inhibitors (NRTIs) to
determine if this is sufficient to suppress HIV replication to spare using
protease inhibitors (PIs) or nonnucleoside reverse transcriptase
inhibitors (NNRTIs), if possible.
B. two NRTIs and the NNRTI efavirenz or >1 PIs.
C. three NRTIs to spare a PI or NNRTI.
7. Drug resistance testing is recommended for . . .
A. pregnant woman who are initiating antiretroviral therapy.
B. patients with chronic, asymptomatic HIV infection before therapy.
C. patients with suboptimal viral load suppression after initiation of
HAART.
D. patients with clinical evidence of drug failure before changing or
interrupting the antiretroviral drugs.
E. both C and D.
8. Before initiating HAART, the health-care provider should . . .
A. confirm HIV results.
B. obtain hematology and chemistry panels, lipid levels, assays for
possible coinfections, and CD4+ T cell count (two levels, if possible).
C. obtain plasma HIV ribonucleic acid (RNA) measurements (two levels,
if possible).
D. assess readiness for treatment.
E. perform all of the above.
Goal and Objectives
This MMWR provides recommendations for the use of antiretroviral therapy among adults and adolescents infected with human immunodeficiency virus (HIV).
These recommendations were developed by CDC staff and the Panel on Clinical Practices for Treatment of HIV. The goal of this report is to provide evidence-based
general guidance for using antiretroviral agents in treating HIV-infected adolescents and adults, including pregnant women. Upon completion of this activity, the
reader should be able to describe 1) considerations for initiating antiretroviral therapy; 2) optimal adherence to therapy; 3) considerations for changing therapy and
available therapeutic options; 4) use of testing for antiretroviral drug resistance; 5) considerations for using antiretroviral therapy among adolescents; and
6) considerations for using antiretroviral therapy among pregnant women.
To receive continuing education credit, please answer all of the following questions.
9. Methods to improve adherence include . . .
A. chastising patients for failing to take medications.
B. supporting and reinforcing the need for optimal adherence.
C. ongoing patient education and after-hours access to health-care
providers.
D. all of the above.
E. B and C only.
10. Which of the following are reasons to consider changing antiretroviral
therapy?
A. An occasional increase in plasma HIV RNA from <50 copies/mL to
51–500 copies/mL in a patient who has previously maintained
undetectable plasma viremia.
B. Systemic or specific toxicity.
C. Suboptimal suppression of plasma viremia after initiating a regimen.
D. All of the above.
E. B and C only.
11. When considering a change in an antiretroviral regimen, in addition to
performing laboratory evaluations, which of the following is critical?
A. Assessing patient adherence to therapy.
B. Reviewing medications, including both prescription and over-the-
counter medications.
C. Reviewing remaining treatment options.
D. All of the above.
12. If a patient takes St. John’s wort for depression, which of the following





13. Which class of antiretroviral drugs is most likely to be associated with




14. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
15. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.




























































































































































16. I plan to use these recommendations as the basis for . . .  (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.








18. How much time did you spend reading this report and completing the
exam?
A. 1–1.5 hours.
B. More than 1.5 hours but fewer than 2 hours.
C. 2–2.5 hours.
D. More than 2.5 hours.
19. After reading this report, I am confident that I understand the general
guidance for using antiretroviral agents in treating HIV-infected
adolescents and adults, including pregnant women.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. After reading this report, I am confident I can describe considerations
for initiating antiretroviral therapy.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. After reading this report, I am confident I can describe optimal
adherence to antiretroviral therapy.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. After reading this report, I am confident I can describe considerations
for changing therapy and available therapeutic options.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–13.
1. B; 2. B; 3. B; 4. B; 5. B; 6. B; 7. E; 8. E; 9. E; 10. E; 11. D; 12. C; 13. A.
24. After reading this report, I am confident I can describe considerations
for using antiretroviral therapy among adolescents.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. After reading this report, I am confident I can describe considerations
for using antiretroviral therapy among pregnant women.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
26. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
27. The tables and figure are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
29. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
30. How did you learn about this continuing education activity?
A. Internet.
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